CUMULATIVE INDEX 1992

Volume 39

February	MEDICAL GENETICS I, pages 1–198
April	MEDICAL GENETICS II, pages 199–368
June	DEVELOPMENT AND BEHAVIOR: OLDER CHILDREN AND ADOLESCENTS, pages 369–590
August	PEDIATRIC NEUROLOGY, pages 591–953
October	PEDIATRIC EMERGENCY MEDICINE, pages 955–1183
December	ASTHMA, pages 1185–1414

Note: Page numbers of article and issue titles are in **boldface** type.

Abdominal pain, recurrent, 723
Abdominal trauma, definitive care of, 1088–1089
  suspected child abuse in, 1064–1065
Academic advancement, in dysmorphology and clinical genetics, 359–360
ACCESS, for social skills training, 562
Accident proneness, in children, 472–473
Accumulations, in mathematics learning, 529–530
Accutane, as teratogen, 128
Acetylcholine, in muscle function, 827
Acidosis, neurometabolic disorders with, laboratory studies of, 808–809
Acidurias, organic, clinical features of, 809
Acoustic nerve, tumors of, in neurofibromatosis, 602, 604
Acquired immunodeficiency syndrome, of central nervous system, **691–714**
Acromelia, definition of, 283
Activated charcoal, for poisoning, 1036–1037, 1040
Activity level, decreased, in acute asthma, 1312
Adenosine, for supraventricular tachycardia, 978–979
Adenosine triphosphate, in muscle function, 827–828
Adhesion molecules, expression of, in viral respiratory infection, 1271–1272
Adolescents, attention deficits in, **487–512**
  attitudes toward eating among, 390–391
  behavioral assessment of, **369–378**
    content of, 374–376
    functions of, 370–371
    structure for, 372–374
    value of, 376
  central nervous system imaging in, **743–776**
  language disabilities in, **513–524**
  language processing demands on, 518–523
  social skills deficits in, **551–567**
Adrenal hyperplasia(s), congenital, and ambiguous genitalia, 311–312
    molecular genetic analysis of, 98
    neonatal screening tests for, 203
Adrenocorticotropic hormone, release of, in burn injuries, 1155
Affective illness, treatment of, for school failure management, 912–913
Affective matching, skills and competencies in, 556–557
Affinities, in mathematics learning, 530
Aggression, and accident proneness, 473
  as coping strategy, and low self-esteem, 543
AIDS, of central nervous system, **691–714**
Air pollution, and asthma, 1199
Air Power/Air Wise, for asthma self-management, 1345
Airway(s), epithelium of, damage to, in viral respiratory infection, 1270–1272

Airway(s) *(Continued)*
hyperresponsiveness of, and chronic pulmonary inflammation, 1364
in asthma, alpha macroglobulin and, 1215
clinical manifestations of, 1207–1208
development of, 1205–1207
mediators of, 1209–1214
pathogenesis of, 1209–1214
virus-induced, mechanisms of, 1262–1272
in asthma, pathology of, 1214–1217
inflammation of, and airway hyperresponsiveness, 1209, 1364
asthma and, 1193–1195
responsiveness of, and wheezing in infancy, 1189
in asthma, testing of, 1253–1255
to antigen challenge, viral respiratory infection and, 1268
stabilization of, in burns, 1148
Albuterol, for acute asthma, dosage guidelines for, 1315
with medically supervised therapy, 1316–1317
Alcohol, and fetal death, 186
as teratogen, 119–122
Allele, definition of, 106
Allergen(s), and asthma, **1277–1291**
exposure to, and sudden severe bronchospasm, fatality risk in, 1232
evaluation of, 1279–1280
role in asthma, 1278
indoor, 1283–1286
cats, 1284–1285
cockroaches, 1285
dogs, 1285
exposure to, threshold levels for, 1280–1281
house dust mites, 1283–1284
molds, 1285–1286
re-exposure to, and disease, 1281–1282
rodents, 1285
outdoor, 1286–1287
sensitization and, 1277–1278
Allergic factors, in airway hyperresponsiveness, in asthma, 1206–1207
Allergic response, late-phase, development of, 1266–1267
Allergic rhinitis, asthma concomitant with, 1335–1336
Allergic sensitivity testing, in chronic asthma, 1297
Allergy, asthma and, 1191–1193
genetics of, 1195–1197
inhalant, evidence for sensitization in, 1278–1279
Alliance of Genetic Support Groups, 17–18
Alopecia, traction, suspected child abuse in, 1067
Alpha-1–antitrypsin deficiency, confusion with asthma, 1335
molecular genetic analysis of, 98
Alpha macroglobulin, and airway hyperresponsiveness, in asthma, 1215
5–Alpha-reductase deficiency, and ambiguous genitalia, 313
Ambiguous genitalia, genetic aspects of, **307–317**. See also under *Genitalia*.
Aminoacidopathies, neonatal screening tests for, 202
Aminophylline, for acute asthma, with hospitalization, 1320
with medically supervised therapy, 1317–1318
Aminopterin, as teratogen, 122
Amitriptyline, for affective illness, 914
Ammonia, levels of, with forearm ischemic exercise, 836–837
Amnion disruption sequence, 256, 267–270
Amniotic band(s), effects of, 139
Amniotic band syndrome, 235
vascular disruption and, 267
Anaphylaxis, and asthma, 1337
Androgen insensitivity, and ambiguous genitalia, 312–313
Anesthesia, general, for refractory status epilepticus, 1022–1023
Aneurysms, formation of, in Kawasaki disease, 980–981
of central nervous system, imaging of, 753
Angelman syndrome, chromosomal deletion syndrome in, 341
molecular genetic analysis of, 103
uniparental disomy in, 342
Angiofibromas, facial, in tuberous sclerosis complex, 592–593
Angiogenesis, regulation of, 263
Ankle problems, in children's sports, 445–446
Anomalies, definition of, 236–237
Antiasthma drugs. See also under *Asthma* and names of specific drugs.
clinical pharmacology of, 1217–1219
Antibody production, virus-specific, in asthma, 1263
Anticholinergics, for asthma, acute, with hospitalization, 1321
chronic, 1298, 1302–1303
for torsion dystonia, 732
Anticoagulants, toxic effects of, 967
Anticonvulsants, administration of, intramuscular, 1021
intraosseous, 1020–1021

rectal, 1021–1022
and fetal death, 186
as teratogens, 122–125
for intracranial hypertension management, 1122
for status epilepticus, 1015–1023
Antidepressants, for affective illness, 914–915
tricyclic, sodium bicarbonate as antidote to, 1042–1043
Anti-inflammatory drugs, for asthma, clinical pharmacology of, 1218–1219
role of, 1374–1375
Antimanic drugs, for affective illness, 916–917
Antimicrobial agents, for tuberculous meningitis, 664
Antiphospholipid antibodies, and fetal death, 180
Aorta, coarctation of, in infant, circulatory collapse with, 963–964
Aortic stenosis, chest pain in, 976
Apical ectodermal ridge, role in limb reduction defects, 270
Apnea, in trisomy 18, 42
Apophysis, avulsion of, with sports injury, 436
Applications, in mathematics learning, 529–530
Apprehension, in mathematics learning, 529–530
Approaches, in mathematics learning, 529–530
Aqueductal stenosis, magnetic resonance imaging of, 766
Arboviruses, congenital, 684
Arithmetic, problems with, stress-reduction for, 904
test battery items for, 903
Arterial distribution infarction, in full term infant, 631–635
clinical manifestations of, 633
electroencephalography of, 634
imaging studies of, 633–634
outcome in, 634–635
Arterial dysplasia, in neurofibromatosis, 605
Arteriovenous malformation, intramedullary, magnetic resonance imaging of, 758
Arthrogryposis, fetal akinesia sequence and, 243
Ash leaf spot, in tuberous sclerosis complex, 592
Aspergillosis, bronchopulmonary, allergic, and worsening of asthma, 1331
Assault, prevention of, 480–481
ASSET, for social skills training, 562
Asthma, **1185–1382**
action plan for, 1236
acute, **1311–1325**
convalescent phase of, 1322–1323
dosage guidelines for, 1315
early symptoms of, 1312
home therapy for, 1312–1314
hospitalization for, 1319–1321
intensive care for, 1321–1322
medically supervised therapy for, 1315–1319
mortality risk in, 1316, 1323
air pollution and, 1199
airway inflammation in, 1193–1195
airway pathology in, 1214–1217
allergen-specific treatment for, 1287–1288
allergens and, 1191–1193, **1277–1291**, 1335–1337. See also *Allergens*.
and anaphylaxis, 1337
and bronchial responsiveness, 1195
bronchoalveolar lavage studies in, 1364
cancer chemotherapy and, 1371–1372
care of, crisis in, **1225–1241**
primary care physician and, 1236–1237, 1239
cell-cell interactions perpetuating, 1366
children with, growth of, 1337–1338
chronic, **1293–1310**
medication available for, 1298–1299
medication selection for, 1306–1307
physician assessment of, 1296–1297
therapy for, 1297–1298
weekly low-dose methotrexate and, 1373
chrysotherapy and, 1371
complicating features of, **1327–1341**
conditions confused with, 1332–1335
alpha-1–antitrypsin deficiency, 1335
bronchiectasis, 1334
bronchiolitis, 1334
ciliary dyskinesia, 1335
cystic fibrosis, 1334
foreign body aspiration, 1333
habit cough, 1334–1335
hyperventilation syndrome, 1333–1334
panic disorder, 1333–1334
vocal cord dysfunction, 1333
curability of, **1363–1382**
delayed care of, fatality risk in, 1233
development of, respiratory illness in infancy and, 1190–1199
diagnosis of, importance of, 1237–1239
drugs for, clinical pharmacology of, 1217–1219
eosinophils and, 1365
exacerbation of, with viral respiratory infection, 1259–1261
exercise-induced, airway hyperresponsiveness and, 1207–1208
fatality risk in, 1231–1235

Asthma *(Continued)*
identification of, 1235
psychosocial issues in, 1234
flow-volume curves in, 1248
food allergy and, 1282–1283
gender and, 1197
genetics of, 1195–1197
histopathology of, 1364
hospitalization for, rate of, 1229–1231
inhaler for, correct technique with, 1356
long-term outcome in, 1235–1236
mediators in, 1210–1214
morbidity from, 1227–1228
mucoid bronchial impaction with, 1338
nocturnal, airway hyperresponsiveness and, 1208
passive smoking and, 1198–1199
pathogenesis of, 1191–1199, **1205–1224**
patient education in, **1343–1361**
content of, 1352–1356
anatomy and physiology, 1352–1353
early warning signs and severity assessment, 1353
environmental control measures and triggers, 1353
home inhalers and nebulizers, 1355–1356
home management plans, 1353–1354
home monitoring, 1355
medications, 1354
remaining calm, 1354–1355
family coping skills in, 1352
future directions in, 1357–1358
organizations for, 1357
reading material for, 1357
resources for, 1356–1357
poverty and, 1197–1198
prevalence of, 1225–1227
psychosocial problems with, and fatality risk, 1233–1235
pulmonary function testing in, 1238, **1243–1258**. See also *Pulmonary function test(ing)*.
race and, 1197–1198
referral to specialist in, guidelines for, 1239
remission of, attempts to induce, timing of, 1373–1374
following sinusitis treatment, 1370–1371
pharmacologic interventions and, 1371–1374
spontaneous, 1366–1367
with antigen immunotherapy, 1368
with antigen removal, 1367–1368
respiratory infections and, **1259–1276**, 1368–1370. See also *Respiratory infections*.
reversibility of, evidence for, 1366–1371
risk factors for, **1185–1203**, 1282
self-management of, courses available for, 1345
development of, 1344–1345
goals of, 1346–1347
program for, developmentally based, 1349–1351
essential components of, 1346–1352
features of, 1348–1352
rehearsal of, 1348
reinforcement of, 1348
repetition of, 1348
role of, 1345–1346
severity of, airway hyperresponsiveness and, 1207
classification of, 1208
staging of, 1293–1296
spirometry findings in, 1247
therapy of, **1205–1224**
role of anti-inflammatory therapy in, 1374–1375
virus-induced, mechanisms of, 1262
worsening of, conditions associated with, 1328–1332
Asthma Care Training for Kids, 1344–1345
Astrocytoma, cervicomedullary, magnetic resonance imaging of, 766
retinal, in tuberous sclerosis complex, 594
temporal lobe, imaging of, 765
Atelectasis, and cyanosis, in infant, 993
Atlantoaxial subluxation, in Down syndrome, 36–37
Atopy, and asthma risk, 1282
Atrial flutter, 978–980
Atrioventricular septal defect, in infant, congestive heart failure with, 962–963
Attention deficit(s), **487–512**
brain function in, 490–492
clinical characteristics of, 487–490
differential diagnosis in, 488–489
issues of taxonomy in, 489–490
current issues and future directions in, 508
diagnosis of, 577–578
evaluation of, 492–499
computerized, 497–498
interrelationships between diagnostic measures, 499
medical, 492–494
psychometric techniques of, 498–499
rating scales for, 494–497
parent, 494–496
teacher, 496–497
specific aspects of, 497–498
later outcomes in, 507
management of, 499–507
adjunctive interventions, 506–507
classroom interventions, 501–502

controversial treatments in, 507
home interventions, 499–501
medication, 502–506
stimulants, 503–505
neuroanatomy in, 490
neurobiology of, 490–492
temperament vs, 577–579
Attention deficit-hyperactivity disorder, 897–898
neurologic correlates of, 900
Attribution theory, in self-esteem, 540–541
Autism, and mental retardation, 938–939
Autonomic nervous system, altered function of, in viral respiratory infection, 1267–1270
Autosomal inheritance, in birth defects, 239–241
Average children, peer acceptance/rejection of, 555
Avoiding, as coping strategy, and low self-esteem, 542–543

Bacterial meningitis, **651–668**
complement component deficiencies in, 656–657
computed tomography of, 759
definition of, 651
fever as manifestation of, 653–656
pathophysiology of, 652–653
recurrent, cerebrospinal fluid fistula and, 657–663
Bacterial respiratory infections, and asthma, microbiology of, 1261–1262
Ballismus, 738
Barbiturates, for status epilepticus, 1020, 1024–1025
Basal ganglia, calcification of, in HIV-1–related progressive encephalopathy, 702
Basophil histamine, release of, and airway hyperresponsiveness, 1265
Becker muscular dystrophy, complications of, 887
diagnosis of, 884–885, 887
management of, 885–889
molecular genetic analysis of, 99–100
Beclomethasone dipropionate, for asthma, 1304–1305
Bedesonide, for chronic asthma, 1304–1305
Behavior, learning of, 395–397, 399
teaching of, role of discipline in, 397–399
Behavioral interview, in primary care, 372
Behavioral landmarks, in first year, correlation with cerebral glucose metabolism, 781
Behavioral monitoring, in primary care, 373–374
Behavioral observation, in primary care, 372
Behavioral problems, temperament and, 574–575
Behavioral programs, for retentive encopresis, 425
Beliefs and values, cultural, 56
Benzodiazepines, flumazenil as antidote to, 1045–1046
for status epilepticus, 1015–1019
intraosseous administration of, 1020
Beta-adrenergic agents, for asthma, acute, home therapy with, 1313
with hospitalization, 1319
with intensive care, 1321
with medically supervised therapy, 1316–1317
chronic, 1298–1301
clinical pharmacology of, 1217
Beta-adrenergic blockade, in viral respiratory infection, 1267–1269
Beta-blockers, glucagon as antidote to, 1041–1042
11–Beta-hydroxylase deficiency, and ambiguous genitalia, 312
Bicycle helmet, use of, and injury prevention, 477
Biochemical assays, of muscle, in mitochondrial disorders, 331
Biofeedback, for retentive encopresis, 425
Biologic factors, in social disabilities, 552
Biotinidase deficiency, neonatal screening tests for, 203
Birth defects, analytic studies of, 67–68
associations of, 145–146
classification of, 233–237
clinical presentation of, classification by, 75–76
complexes of, 145–146
diagnosis of, 150–156, 237–244
nonsyndromic anomalies, 242–244
syndromes of known cause, 237–241
syndromes of unknown cause, 241–242
examples of, 144–145
genetic counseling for, **229–253**
nonsyndromic anomalies, 246–250
syndromic anomalies, 244–246
monitoring of, 75
multifactorial inheritance of, 145
pathogenetic mechanisms of, 137–142
patients with, approach to, 245
recurrence rates in, 249
registries of, **65–77**. See also *Registries*.
sequences in, 146–148
surveillance of, 66–67
syndromes in, 148–150
types of, 142–150

Birth defects *(Continued)*
isolated vs multiple, 143–145
major vs minor, 142–143
Bite marks, suspected child abuse in, 1068
Blalock-Taussig shunt obstruction, in cyanotic cardiac patient, 972
Blood pressure, effect on cerebral blood flow, 1101
evaluation of, in trauma patient, 1086
Blood vessels, embryonic, altered hemodynamics in, 264–265
emboli and thrombosis of, 264
occlusion of, external compression and, 263–264
vascular disruption of, mechanisms of, 256–265
maturation of, 263
Blunt injury, in trauma patient, definitive care of, 1088–1089
Bone fragments, near joint, in children's sports injuries, 438
Bone lesions, in neurofibromatosis type 1, 45–46
Bone marrow, mitochondrial disease of, 324
Botulism, and cyanosis, in infant, 1001
Brachial artery, infarction of, limb reduction with, 265
Brachydactyly, definition of, 284
in young child, 301
Brachymetacarpy, definition of, 284
Bradykinesia, in parkinsonism, 729
Brain, compartmentalization of, 1096
complications in, in cyanotic cardiac patient, 973
functional imaging of, **777–799**
glucose utilization by, in first year, 779–781
hernation of, as source of brain injury, 1097–1098
higher functions of, evaluation of, in school failure, 902
injury to, primary vs secondary, 1095
malformations of, and mental retardation, 934–936
medulloblastoma of, therapy of, 859–862
metabolic disorders of, and mental retardation, 935
Brain waves, in attention deficits, 491
Brainstem gliomas, therapy of, 862–865
Breastfeeding, and wheezing, in infancy, 1187–1188
Breath-holding spells, and cyanosis, in infant, 998–999
and syncope, 718
Breathing, during suckling, 381
normal, flow-volume graph of, 1244
Bronchial challenge testing, of airway reactivity, in asthma, 1254–1255
Bronchial hyperresponsiveness, asthma and, 1195
genetics of, 1195–1197
relevance to allergy, 1277–1278
Bronchiectasis, confusion with asthma, 1334
Bronchiolitis, and cyanosis, in infant, 994
confusion with asthma, 1334
Bronchodilators, airway reactivity testing with, in asthma, 1253–1254
for asthma, chronic, 1298–1303
delivery systems for, 1300
clinical pharmacology of, 1217–1218
Bronchopulmonary aspergillosis, allergic, and worsening of asthma, 1331
Bronchopulmonary dysplasia, and cyanosis, in infant, 994
Bronchoscopy, for inhalation injury, in burns, 1151–1152
Bronchospasms, severe, sudden onset of, fatality risk in, 1232
Bronchus(i), mucoid impaction of, with asthma, 1338
Bruises, suspected child abuse in, 1068
Bullying, as coping strategy, and low self-esteem, 543
Burns, **1145–1163**
burn center care of, 1150–1152
criteria for, 1149
daily wound care in, 1156–1158
emergency management of, 1147–1150
epidemiology of, 1145–1147
estimation of, diagram for, 1153
extent and depth of, 1152–1153
field resuscitation in, 1148–1149
infection in, 1157
metabolic changes in, 1155–1156
nutritional support in, 1155–1156
prevention of, 1147
rehabilitation in, 1161–1162
suspected child abuse in, 1056–1062, 1146
characteristics of, 1056–1058
types of, 1058–1062
contact, 1060–1062
scalding, 1058–1060
wound excision in, 1158–1161
wound management in, 1148
Bypass techniques, for mathematics underachievement, 533

Cafe-au-lait lesions, in neurofibromatosis, 600–601
Calcific vasculopathy, in HIV-1–related progressive encephalopathy, 703
Calcium, accumulation of, with rhabdomyolysis, 832
in muscle function, 827–828

Calcium channel blockers, glucagon as antidote to, 1041–1042
Calf muscles, pseudohypertrophy of, in Duchenne muscular dystrophy, 888
CALM: Childhood Asthma, Learning to Manage, 1345
Calvarial bone density, in osteogenesis imperfecta, 295, 299
Campomelic dysplasia, skin signs in, 286
Cancer, in genomic imprinting, 343
Cancer chemotherapy, effect on asthma, 1371–1372
Capillary plexus, formation and disruption of, 257–258
Capital femoral epiphysis, slipped, in children's sports injury, 439
Captain Respitore to the Rescue, for asthma self-management, 1345
Carbamazepine, and fetal death, 186
  as teratogen, 123–124
  for manic illness, 917–918
Carbohydrate metabolism, disorders of, and rhabdomyolysis, 834–841
    differential features of, 848–849
Carbon dioxide tension, effect on cerebral blood flow, 1101
Carbon monoxide, and cyanosis, in infant, 1001 1002
Cardiac issues, in emergency room, **955–985**
Cardiac medications, adverse reactions to, medical management of, 965–967
Cardiac patient, in emergency room, cyanotic, 971–973
    medical management of, 964–982
Cardiac rhabdomyoma, in tuberous sclerosis complex, 599
Cardiac system, in cyanosis, 989–992
Cardiomegaly, in infant, congestive heart failure with, 962
Cardiomyopathy, with Duchenne muscular dystrophy, 888
Cardiopathy, hypertrophic obstructive, chest pain in, 976
Cardiovascular system, embryonic, 259
Cardioversion, for supraventricular tachycardia, 979
Career development, in dysmorphology and clinical genetics, **349–362**
Carnitine palmitoyl transferase deficiency, and rhabdomyolysis, 841–843
    differential features of, 848–849
Carotid artery, occlusion of, in neurofibromatosis, 605–606
Catecholamine systems, in attention deficits, 491
Catharsis, for poisoning, 1037–1038
Cats, as allergens, in asthma, 1284–1285
Cavernous angioma, magnetic resonance imaging of, 755
Cell-cell interactions, asthma perpetuation by, 1366
Cellular immune response, viral effects on, in asthma, 1263–1264
Central nervous system, abnormalities of, and fetal death, 184–185
  AIDS infection of, **691–714**
  developmental malformations of, magnetic resonance imaging of, 745–750
  HIV-1–associated conditions of, 691–694, 707–709
  imaging of, **743–776**
  infection of, imaging of, 759–762
  malformations of, and mental retardation, 934–936
  neoplastic diseases of, imaging of, 763–770
  trauma to, computed tomographic imaging of, 750–753
  tumors of, changes in approach to, **859–877**
    delay in diagnosis of, reasons for, 872
    methotrexate for, risks with, 870–871
    radiation for, effects of, 865–873
      patient age and, 871–873
      risk factors with, 868–873
      volume of, 869–870
    survival rates in, 859–865
    treatment complications in, 865–873
  vascular disease of, imaging of, 753–759
Cereal, introduction into diet, 385
Cerebral abscesses, computed tomography of, 762
Cerebral atrophy, in HIV-1–related progressive encephalopathy, 701, 704–705
  in Sturge-Weber syndrome, 610–611
Cerebral blood flow, maintenance of, 1100–1101
Cerebral dysfunction, historical background on, 896–898
  stress reduction in, 904
Cerebral dysgenesis, and mental retardation, 934–935
Cerebral glucose utilization, ontogenetic changes in, 779–784
Cerebral hemorrhage, in preterm infant, 635–639
    clinical manifestations of, 635–637
    imaging of, 637–638
    outcome in, 639
  ultrasonography of, 750
  with ventricular catheter, 1113
Cerebral hypoperfusion, in full-term infant, 623–631
    clinical manifestations of, 624–627
    electroencephalography of, 630–631
    imaging studies of, 627–629
    neurologic course in, 623–624

Cerebral hypoperfusion *(Continued)*
outcome in, 631
in preterm infant, 639–646
clinical manifestations of, 641–643
imaging studies of, 643–645
outcome in, 645–646
Cerebral infarction, computed tomography of, 757
Cerebral oxygen metabolism rate, correlation with Glasgow coma scale, 1106
Cerebral palsy, and mental retardation, 939
dystonia in, 734
future neuroimaging of, 794–795
mild, and clumsiness, 447
positron emission tomography of, 789
with cerebral hypoperfusion in preterm infant, 645
with perinatal arterial distribution infarction, 634
Cerebral perfusion, in traumatic head injury, 1099–1105
Cerebral tumors, imaging of, 764
Cerebrospinal fluid, removal of, in post-traumatic intracranial hypertension, 1120
studies of, in HIV-1–related progressive encephalopathy, 702–703
Cerebrospinal fluid fistula, and recurrent bacterial meningitis, 657–663
otogenic, 661–662
sites of, 659
spinal defects and, 662–663
Cerebrospinal fluid rhinorrhea, and recurrent bacterial meningitis, 657–661
Cerebrovascular disease, perinatal, **621–650**
Cervicomedullary astrocytoma, magnetic resonance imaging of, 766
Charcoal, activated, for poisoning, 1036–1037
advantages and disadvantages of, 1040
Chemicals, as teratogens, 119–129
Chest, discomfort in, in acute asthma, 1312
pain in, in cardiac patient, 974–977
skeletal dysplasia of, 291, 295
Child abuse, **1053–1081**
recognition of, 1053–1054
sexual, 1070–1078. See also *Sexual abuse*.
suspected, abdominal injuries, 1064–1065
burns, 1056–1062
cutaneous lesions, 1067–1069
documentation of, 1070
head trauma, 1065–1067
history taking in, 1054–1055
management and follow-up of, 1078–1079
physical examination in, 1056
reporting of, 1078
skeletal injuries, 1062–1064
Childhood mortality, in Down syndrome, 33–34
Children, accident-prone, 472–473
attitudes toward eating among, 390–391
behavioral assessment of, **369–378**
content of, 374–376
functions of, 370–371
structure for, 372–374
value of, 376
coma scale for, 1107
disabled, definition of, 456–458
participation in educational system, 466–467
pediatrician participation with, 462–463
service delivery to, case illustrations of, 464–466
eating behavior in, development of, **379–394**
injury control in, **471–485**
language disabilities in, **513–524**
older, discipline of, 408, 410
social skills deficits in, **551–567**
peer acceptance of, 555–556
school-aged, attention deficits in, **487–512**
temperament issues in, **569–584**
sports injuries in, **433–449**
Chlamydia infection, suspected sexual abuse in, 1076
Cholinergic antagonists, for asthma, clinical pharmacology of, 1218
Cholinergic stimulation, in viral respiratory infection, 1269–1270
Chondromalacia, in children's sports injury, 440–441
Chorea, 735–736
Choreoathetosis, kinesigenic, 734
paroxysmal, 721
Choriomeningitis, congenital, 684
Chorioretinitis, with congenital cytomegalovirus, 679
with congenital toxoplasmosis, 675
Chromosomal deletion syndromes, in genomic imprinting, 340–342
Chromosome(s), abnormalities of, and ambiguous genitalia, 310–311
and fetal death, 163–166
and mental retardation, 931–934
diagnosis of, 237–238
Chromosome studies, for genetic disorders, 96, 232
in pregnancy loss, 161–162
in skeletal dysplasia, 303
Chrysotherapy, and asthma, 1371

Cigarette burns, suspected child abuse in, 1062
Ciliary dyskinesia, confusion with asthma, 1335
Circulation, embryonic, disruption of, 256–257
  in status epilepticus, 1012–1013
Circulatory volume, evaluation of, in trauma patient, 1086
Cleft lip/palate, 141
Cleidocranial dysplasia, in neonate, 300
Clinical genetics, fellowship and career development in, **349–362**. See also under *Dysmorphology and clinical genetics*.
  training in, minimum requirements of, 351–352
Clonidine, for attention deficits, 504, 506
  naloxone as antidote to, 1041
Clowning, as coping strategy, and low self-esteem, 543
Club foot, pathogenesis of, 271
Clumsy child, 446–448
Coarctation of aorta, in infant, and circulatory collapse, 963–964
Cocaine, and fetal death, 186
  as teratogen, 125–126
  role in vascular disruption, 272–273
Cocaine abuse, chest pain in, 977
Cockroaches, as allergens, in asthma, 1285
Cognitive ability, relationship to temperament, 576
Cognitive processing, deficits in, 515–518
    metalinguistic functioning, 516
    problem solving, 516–517
    processing speed, 517–518
    verbal short-term memory processes, 515–516
  linguistic weakness in, in adolescence, 518–523
Cognitive training, for attention deficits, 507
Colloid fluids, for burns, 1154
Coma, barbiturate-induced, for refractory status epilepticus, 1024–1025
Coma scale, children's, 1107
  Glasgow, 1105
Comminuted fractures, suspected child abuse in, 1063
Communication, cultural factors in, and genetics, 59–62
Competence, identification of, in reinforcing self-esteem, 544–548
Complement component, deficiencies of, in bacterial meningitis, 656–657
Computed tomography, for cerebral hypoperfusion, 627
  of central nervous system, primary uses of, 744
  of facial fractures, 1140
Concepts, in mathematics, 528, 530
Condylomata acuminata, suspected sexual abuse in, 1077–1078
Confidentiality, ethical issues in, 84–85
Congenital anomalies, multiple, mental retardation with, 936–937
Congenital infections, serial evaluations for, 686
Congestive heart failure, in infant, lesions presenting with, 961–963
Consequences, creation of, in reinforcing self-esteem, 547
Contact burns, suspected child abuse in, 1060–1062
Continuing education, in dysmorphology and clinical genetics, 357
Continuous Performance Task, for attention deficit evaluation, 497
Contribution, sense of, in reinforcing self-esteem, 545–546
Controversial children, peer acceptance/rejection of, 556
Coping, strategies for, and self-esteem, 541–544
  temperament and, 580
Cori-Forbes disease, and rhabdomyolysis, 840
Coronary artery anatomy, anomalous, chest pain with, 976
Corpus callosum, absence of, and fetal death, 185
  dysgenesis of, magnetic resonance imaging of, 745
Cortical defects, in tuberous sclerosis complex, 596
Cortical dysplasia, magnetic resonance imaging of, 749
  with seizures, positron emission tomography of, 790
Corticosteroids, for acute asthma, dosage guidelines for, 1315
    home therapy with, 1314
    with hospitalization, 1320
    with medically supervised therapy, 1318
  for tuberculous meningitis, 665
Cortisol, release of, in burn injuries, 1155
Cough, habit, confusion with asthma, 1334–1335
  increased, in acute asthma, 1312
Cranial fossa, anterior, cerebrospinal fluid fistula of, and recurrent bacterial meningitis, 657–661
Cromolyn sodium, for asthma, chronic, 1298, 1303
    clinical pharmacology of, 1219
    stage 2, 1295
Croup, and cyanosis, in infant, 995
Crystalloid fluids, for burns, 1154

Cultural/ethnic factors, in social disabilities, 554
Culture, and genetics, 56–58
Curriculum adjustment, for school failure management, 911–912
Cutaneous lesions, suspected child abuse in, 1067–1069
Cutis laxa syndrome, 140
Cyanosis, definition of, 988
in acute asthma, 1312
in infant, **987–1006**
algorithm for, 956
cardiac system in, 989–992
evaluation of, 987
pathophysiology of, 988–989
presentation of, 956–961
central vs peripheral, 956–957
pulmonary blood flow in, 958–961
pulmonary vs cardiac origin, 957–958
pulmonary system in, 992–994
stabilization of, 987
Cylert, for attention deficits, 504–505
Cystic fibrosis, and cyanosis, in infant, 994
carrier testing for, 220
arguments for and against, 223
population-based, 221–225
recommendations regarding, 224
chromosome mutation analysis in, 217
confusion with asthma, 1334
definitive therapy for, prospects of, 225
expected genotypes in, 217
gene for, cloning of, 214–215
implications for patient, 217–218
mutations of, 215–216
genetic counseling in, 219–221
genetic testing for, **213–228**
incidence of, 213–214
molecular genetic analysis of, 98–99
mutation detection in, effect of, 222
neonatal screening tests for, 203
phenotype-genotype correlations in, 218–219
Cytomegalovirus, and fetal death, 182
as teratogen, 116
congenital, 678–681
of brain, computed tomography of, 761
Cytoplasmic inheritance, 336–337

Dandy-Walker cyst, of brain, magnetic resonance imaging of, 747
Dantrolene, for malignant hyperthermia, 846
Database and record system, in dysmorphology and clinical genetics, 358–359
Daydreaming, 722
Debrancher enzyme, deficiency of, and rhabdomyolysis, 840
Decision-making opportunities, in reinforcing self-esteem, 546
Deformation, definition of, 137–138, 233
Deformation sequence, definition of, 148
Demyelination syndrome, of brain, magnetic resonance imaging of, 763
Denying, as coping strategy, and low self-esteem, 543
Depakene, as teratogen, 124–125
Depression, childhood, criteria for, 906
Dermal sinus, congenital, and cerebrospinal fluid fistula, 662
Desipramine, for affective illness, 914
Details, in mathematics, 526, 530
Development, susceptible stages of, 112
Developmental considerations, in asthma self-care, 1349–1351
in behavioral assessment, 375
Developmental factors, in social disabilities, 552–553
Developmental malformations, of central nervous system, imaging of, 745–750
Dexadrine, for attention deficits, 504–505
Dexamethasone, for bacterial meningitis, 653
Dextroamphetamine, for attention deficits, 504–505
Dextromethorphan, and cyanosis, in infant, 1001
Dextrose, administration of, in poisoning, 1032
Diabetes mellitus, maternal, as teratogen, 118
Diagnostic referencing, computerized, in pediatric emergency medicine, **1165–1174**
application of, 1170–1173
Diaphyses, fractures of, suspected child abuse in, 1063
in skeletal dysplasia, 291
Diarrhea, chronic, treatment of, 423
Diastrophic dysplasia, in neonate, 288
Diazepam, for status epilepticus, 1016, 1017
rectal administration of, 1022
Diethylstilbestrol, as teratogen, 126
Digits, reduction of, pathogenesis of, 271
Digoxin, Fab antibody fragments as antidote to, 1044–1045
for supraventricular tachycardia, 979
toxic effects of, 965–966
2,3–Dimercaptosuccinic acid, as lead poisoning antidote, 1043–1044
Disc herniation, spinal, in children's sports injury, 446
Discipline, **395–411**
reasons for, 397–399
internalizing society's values, 398–399

stopping inappropriate/undesirable behavior, 397
teaching a lesson, 398
teaching appropriate behavior, 398
techniques of, 399–410
time-in, 400
time-out, 400–407
with older children, 408, 410
Disomy, uniparental, 338
in genomic imprinting, 341–343
Disruption, definition of, 137–140, 234, 255
Disruption sequence, definition of, 148
Diuretics, toxic effects of, 967
DNA, definition of, 105–106
DNA hybridization, in molecular genetic diagnosis, 92–93
DNA probes, in molecular genetic diagnosis, 92
DNA technology, and newborn screening, 209–210
Dogs, as allergens, in asthma, 1285
Dopamine agonists, for parkinsonism, 730
Down syndrome, and mental retardation, 931
anticipatory guidance and health supervision in, 33
atlantoaxial subluxation in, 36–37
central nervous system malformations in, magnetic resonance imaging of, 747
congenital heart disease in, 34
growth and development in, 38–39
hearing loss in, 35
immunizations in, 39
infant-childhood mortality in, 33–34
management of, guidelines for, 32–39
medical complications in, 39
ophthalmologic abnormalities in, 37–38
phenotypic range of, 165
therapeutic options in, 39
thyroid disorders in, 35–36
Doxepin, for affective illness, 915
Drugs, as teratogens, 119–129
Duchenne muscular dystrophy, **879–894**
complications of, 887
diagnosis of, 881–885
abnormal gait, 881
electromyography, 883
immunoblot, 887
muscle biopsy, 883–884
gene for, 882
management of, 885–889
molecular genetic analysis of, 99–100
treatment of, 889–891
Duodenal hematoma, suspected child abuse in, 1065
Dust mites, sensitization/exposure to, and asthma risk, 1282
Dwarfism, spondyloepiphyseal dysplasia congenita and, 236
Dyskinesias, paroxysmal, and dystonia, 734
Dysmorphologic disorders. See also *Birth defects*.
definition of, 135
diagnosis of, **135–156**
algorithm for, definition of malformation sequences and syndromes, 155
discrimination of dysplasias and disruptions, 153
initial evaluation and categorization, 152
scheme for multiple deformations, 154
history of, elements of, 151
occult abnormalities in, 136
pathogenetic mechanisms of, 137–142
prognosis in, 136
recurrence risk of, 136–137
syndromes of, 149–150
treatment options in, 136
Dysmorphology and clinical genetics, academic advancement in, 359–360
ancillary needs and expenses in, 357–359
career development in, **349–362**
goals and objectives of, 353
clinical services of, 354
faculty promotions in, 360–361
fellowship training in, **349–362**
curriculum objectives for, 350–353
job choice in, 353–354
professional visibility and reputation in, 356
research activities in, 355–356
staff and research support in, 354
teaching activities in, 356–357
Dysplasia, definition of, 140–141, 234
Dyssegmental dysplasia, in stillborn, 296
Dystonia, 731
causes of, 733–735
in parkinsonism, 730
Dystonia musculorum deformans, 721
Dystrophies, and clumsiness, 447

Ear, external, lacerations of, treatment of, 1135–1136
Early amnion rupture sequence, and fetal death, 166–168
Eating, attitudes toward, among children and adolescents, 390–391
of solid food, transition to, 384–385
regulation of, 386–389
Eating behavior, and obesity, 385–386
development of, **379–394**

Eating behavior *(Continued)*
food preferences/aversions and, 389–390
measurement of, 379–380
self-regulation of, 388–389
variability in, 388
Ebstein's anomaly, cyanosis in, in infant, 991
Economic factors, in social disabilities, 554
Education, for all handicapped children, 454–455
legislation for, 452, 454–458
findings leading to, 453
least restrictive environment provision of, 456
procedural safeguards for, 455–456
Educational performance, disability and, 457
Electrical burns, in children, 1146
Electroencephalography, in intraventricular hemorrhage, 638–639
in perinatal arterial distribution infarction, 634
in perinatal cerebral hypoperfusion, 630–631
in periventricular leukomalacia, 638–639
Electrographic monitoring, intracranial, chronic, with epilepsy, 792–793
Electron microscopic analysis, of muscle, in mitochondrial disorders, 331
Electron transport chain subunits, 325
Ellis-van Crevald syndrome, newborn with, 289
Embryo, death of, teratogens and, 113–114
Embryonic arteries and veins, disruption of, 260–263
Embryonic circulation, disruption of, 256–257
Emergency medicine, computerized diagnostic referencing in, **1165–1174**
Emergency room, cardiac issues in, **955–985**
Emesis, in poisoning, 1035
Emotional factors, in social disabilities, 553
Encephalitis, congenital, 684
imaging of, 760
in HIV-1–related progressive encephalopathy, 703
Encephalocele, and cerebrospinal fluid rhinorrhea, 660
and fetal death, 185
Encephalofacial angiomatosis, classification of, 609
Encephalomalacia, cystic, with cerebral hypoperfusion in preterm infant, 644
with congenital herpes simplex virus, 683
Encephalomyelitis, magnetic resonance imaging of, 760
Encephalomyopathies, mitochondrial, 323
Encephalopathy(ies), HIV-1–related,
definition of, 694
progressive, 694–707
cerebrospinal fluid studies in, 702–703
clinical features of, 697
course of, 697–698, 706
diagnosis of, 704–707
in school-age children, 700–701
mental deterioration in, 699
mental development in, 695
neuroepidemiology and natural history of, 694–697
neuroimaging findings in, 701–702
spinal cord abnormalities in, 703–704
therapy for, 707
static-stable, 699
transfusion-acquired, 701
hypoxic-ischemic, future neuroimaging of, 793–794
neonatal, 625–626
Encopresis, **413–432**
assessment of, 422–423
definition of, 422
functional, 422–428
prevalence of, 422
treatment of, 423–428
protocols for, 425–428
active, 426–428
conservative, 426
Encouragement, in reinforcing self-esteem, 546–547
Endocarditis, infective, antibiotic prophylaxis for, 969
in cardiac patient, 967–969
patient risk for, 967
procedural risk for, 968
Endocrine system, effect of central nervous system radiation on, 866–867
mitochondrial disease of, 324
Endogenous bronchodilator, loss of, in viral respiratory infection, 1271
Endotracheal tubes, for acute asthma, with intensive care, 1321
Energy deficiencies, neurometabolic, 802
Enteroviruses, congenital, 684
Enuresis, assessment of, 417–418
behavioral management of, **413–432**
definition of, 416
functional, 416–422
prevalence of, 417
treatment of, 418–422
behavioral, 420
pharmacologic with, 421–422
dry bed training, 420
hypnotherapy, 421
medication, 419
psychotherapy, 421

urine alarm, 419–420
urine retention and sphincter control exercises, 420–421
Environment, modification of, for injury prevention, 477–478
Eosinophils, and asthma, 1365
Epidural hematoma, computed tomography of, 751
suspected child abuse in, 1067
with head injury, life-threatening nature of, 1109
Epiglottitis, and cyanosis, in infant, 995
Epilepsy, functional brain imaging for, 784–793
infantile spasms, 785–789
partial epilepsy, 785
in Sturge-Weber syndrome, 609
in tuberous sclerosis complex, 594
juvenile myoclonic, 739
Epinephrine, subcutaneous, for acute asthma, 1317
Epiphyses, dysplasia of, 284
multiple, 292
fractures of, suspected child abuse in, 1062–1063
in skeletal dysplasia, 291
Escharotomy, for burns, 1159–1160
incision sites for, 1151
Estimations, in mathematics learning, 528, 530
Ethanol, flumazenil as antidote to, 1045
Ethical issues, in confidentiality, 84–85
in genetics, **79–89**
counseling, 79–81
prenatal diagnosis, 85–86
screening, 82–83
therapy, 86–88
Ethnocentrism, and genetics, 56–57
Ethnocultural approaches, to genetics, **55–64**
Etretinate, as teratogen, 128
Expressive language, subtle weakness in, in adolescence, 521–523
Eyebrow, lacerations of, treatment of, 1135

Fab antibody fragments, as poisoning antidote, 1044–1045
Face, angiofibromas of, in tuberous sclerosis complex, 592–593
fractures of, treatment of, 1138–1141
lacerations of, foreign particles in, 1132
pain control in, 1132–1133
repair of, 1131–1132
treatment of, 1133–1134
Facial nerve, laceration of, repair of, 1135
Facts, in mathematics learning, 525–526, 530
Failure, role in self-esteem, 547–548
Failure to thrive, suspected child abuse in, 1069–1070
Fallot, tetralogy of, cyanosis in, 959–960, 990
Familial anomalies, genetic counseling in, 247
Familial factors, in social disabilities, 553–554
Family history, acquisition of, cultural factors in, 62–63
Fatigue, increased, in acute asthma, 1312
Fatty acid(s), mitochondrial metabolism of, 842
oxidation disorders of, 815–816
Feedback, in learning, 396–397
positive, in reinforcing self-esteem, 546–547
Feeding, breast- vs bottle-, 381–383
difficulties with, in trisomy 18, 41–42
early, and growth, 383–384
Fellowships, in dysmorphology and clinical genetics, 350–353
Fenoterol, and increased airway reactivity, 1300
Fetal akinesia sequence, 243
Fetal alcohol syndrome, 119–122
Fetal autopsy, in pregnancy loss, 163
Fetal death, absence of corpus callosum and, 185
alcohol and, 186
anticonvulsants and, 186
antiphospholipid antibodies and, 180
carbamazepine and, 186
causes of, 163–186
chromosome abnormalities and, 163–166
cocaine and, 186
cytomegalovirus and, 182
early amnion rupture sequence and, 166–168
encephalocele and, 185
Fryns syndrome and, 172–174
holoprosencephaly and, 185
human parvovirus 19 and, 182
hydrops fetalis and, 182–183
immunologic causes of, 178–181
infections and, 181–182
isotretinoin and, 186
lithium and, 186
malformations in twins and, 175–178
maternal infection and, 182
Meckel-Gruber syndrome and, 168–169
Neu-Laxova syndrome and, 171–172
nonchromosomal multiple malformation syndromes and, 167–174
Pena-Shokeir syndrome and, 171–173
Potter phenotype and, 183–184
renal agenesis and, 183–184
skeletal abnormalities and, 174–175

Fetal death *(Continued)*
teratogenic causes of, 113–114, 185–186
valproic acid and, 186
Walker-Warburg syndrome and, 169–171
Fetal hydantoin syndrome, 122–124
Fetal warfarin syndrome, 129
Fever, in bacterial meningitis, 653–656
Figurative language, subtle weakness in, in adolescence, 520–521
Filter paper technology, in newborn screening, uses for, 210
Fingers, amputations of, amniotic bands and, 139
Flail chest, in trauma patient, definitive care of, 1088
Flame burns, 1146
Flow-volume graph, of breathing, in asthma, 1248
normal, 1244
Fluid replacement, in acute asthma, with hospitalization, 1320
Fluid resuscitation, in burns, 1148, 1154
Flumazenil, as poisoning antidote, 1045–1046
Flunisolide, for asthma, maximum recommended doses for, 1304
Fluoxetine, for affective illness, 915
Fluticasone propionate, for chronic asthma, 1305
Food allergy, asthma caused by, 1282–1283
asthma concomitant with, 1336–1337
Food preferences/aversions, and eating behavior, 389–390
Forearm ischemic exercise, 836–837
Foreign body aspiration, and cyanosis, in infant, 995
confusion with asthma, 1333
Fractures, radiographic age of, 1064
suspected child abuse in, 1062–1063
Fragile-X mental retardation, 932–934
molecular genetic analysis of, 100
Frontal lobe hemorrhage, magnetic resonance imaging of, 754
Fryns syndrome, and fetal death, 172–174
Furosemide, toxic effects of, 967

Galactokinase deficiency, neonatal screening tests for, 203
Galactosemia, neonatal screening tests for, 203
Gamma globulin, for Kawasaki disease, 981
Gardnerella infection, suspected sexual abuse in, 1076–1077
Gastric decontamination, for poisoning, 1033–1041
choice of, 1039–1041
Gastric emptying, for poisoning, 1033–1034
Gastric lavage, for poisoning, 1035–1036
advantages and disadvantages of, 1040
Gastroesophageal reflux, and cyanosis, in infant, 998
and worsening of asthma, 1329–1331
with abnormal movements, 733
Gastrointestinal disorders, congestive heart failure exacerbation in, 969
neurologically based, 723
Gender, and asthma, 1197
Gene, single abnormalities of, and ambiguous genitalia, 311–314
Gene therapy, for Duchenne muscular dystrophy, 890
General anesthesia, for refractory status epilepticus, 1022–1023
Genetic analysis, basic concepts of, 93–97
of mutations, direct, 94–95
indirect, 95–97
Genetic counseling, **229–253**
agenda in, 230–231
confidentiality in, 84–85
cultural factors in, 59
definition of, 229–231
diagnosis in, 230–231
ethical issues in, 79–81
evaluation in, 231–237
for birth defects, 244–250
methods of, 232–233
preparation and data gathering in, 230
with Duchenne muscular dystrophy, 889
Genetic diagnosis, molecular analysis in, **91–109**. See also *Molecular analysis*.
Genetic disorders, **25–53**
correct diagnosis of, 27–29
dystonia in, 735
general principles of, 27–32
genetic counseling in, 32
management of, guidelines for, 32–49
natural history of, 29–30
psychosocial support for, 31–32
registries of, **65–77**. See also *Registries*.
routine screening tests in, 30–31
support groups for, **13–23**
alliance of, 17–18
collaboration of, 19–20
history of, 14–17
role in pediatric services, 21–22
role of professional in, 20–21
survey of, 18–19
therapeutic interventions in, 31
well-child care, 26–27
Genetic markers, definition of, 107–108
identification of, 96–97
Genetic screening, ethical issues in, 82–83

Genetic testing, definition of, 82
for cystic fibrosis, **213–228**
Genetic therapy, ethical issues in, 86–88
Genetic variation, 93–94
Genetics, clinical, fellowship and career development in, **349–362**. See also *Dysmorphology and clinical genetics*.
cultural factors in, **55–64**
communication, 59–62
diagnosis and treatment, 63
health/illness beliefs, 58–59
history acquisition, 62–63
definitions in, 105–108
development of, 1–2
ethical issues in, **79–89**
newborn screening for, practitioner's role in, **199–211**. See also *Newborn screening*.
nontraditional inheritance in, **335–348**
of ambiguous genitalia, **307–317**
Genetics services, clinical, **1–12**
diagnostic examination in, 5–7
economic aspects of, 10–11
genetic counseling in, 7–9
genetic evaluation in, 4–5
history of, 1–2
indications for referral, 3–4
providers of, 9–10
Genitalia, ambiguous, **307–317**
counseling and prenatal diagnosis in, 314–315
evaluation of infant with, 309–310
genetic entities leading to, 310–314
physical examination of, 309
external examination of, 1073
female, prepubertal anatomy of, 1072
male, normal development of, 309
Genomic imprinting, 338–347
cancer in, 343
genes and disorders involving, 339
human triploids in, 340
mammalian, evidence for, 338–339
mechanism of, 347
patterns of inheritance in, 345–346
pedigrees for, 345
pronuclear transplantation in, 339–340
transgene expression in, analysis of, 344
uniparental disomy in, 342–343
Genotype, definition of, 106
Germline mosaicism, 337
Getting Along with Others, for social skills training, 562
Giant cell astrocytomas, in tuberous sclerosis complex, 595
Gingival frenulae, multiple, in Ellis-van Crevald syndrome, 289
Glasgow coma scale, 1105
score with, correlation with mortality, 1106
Glossoptosis, and cyanosis, in infant, 995–996
Glucagon, as poisoning antidote, 1041–1042
Glucocorticoids, for asthma, chronic, 1298, 1303–1306
clinical pharmacology of, 1218–1219
maximum recommended doses for, 1304
stage 3, 1295–1296
stage 4, 1296
Glucose, cerebral utilization of, by age, 782
in temporal lobe epilepsy, 786–787
ontogenetic changes of, 779–784
developmental, 781–783
in first year, 779–781
neurologic correlation with, 783
relation to brain plasticity, 783–784
Glycogen, muscle accumulation of, with myophosphorylase deficiency, 838
Glyco(geno)lysis, anaerobic, in skeletal muscle, 829
Glycogenosis, and rhabdomyolysis, 834–840
Glycoprotein degradation disorders, in older child, detection of, 815
Gonadal dysgenesis, and ambiguous genitalia, 311, 313
Gordon Diagnostic System, for attention deficit evaluation, 497
Gowers' sign, in Duchenne muscular dystrophy, 880
Grasp marks, suspected child abuse in, 1068
Grass pollen, as allergen, 1286–1287
Gray matter, neurometabolic disorders of, 802
Great arteries, transposition of, cyanosis in, 958–959, 991
Grounding, as discipline technique, 409
Growth, and development, in Down syndrome, 38–39
early feeding behavior and, 383–384
failure of, central nervous system radiation and, 866
in children with asthma, 1338
retardation of, teratogens and, 113–114
Growth plate, fractures of, Salter-Harris classification of, 437
problems with, in children's sports, 433–437
Guidelines, creation of, in reinforcing self-esteem, 547
Gunshot wounds, definitive care of, 1090
Gut dialysis, for poisoning, 1037

Hallervorden-Spatz disease, dystonia in, 734

Halothane, for refractory status epilepticus, 1024
Hamartomas, in tuberous sclerosis complex, 591
Handicapped children, definition of, 456–458
Hands, skeletal dysplasia of, 300–302
Haplotype, definition of, 106
Head, circumference of, in HIV-1–related progressive encephalopathy, 704–705
  skeletal dysplasia of, 295, 299
Head injury, 716–717, **1093–1125**
  clinical management of, 1108–1122
  intracranial lesions with, classification of, 1109
  level of consciousness with, 1109
  neurologic assessment and outcome in, 1105–1108
  quantitative assessment of, 1093
  traumatic, pathophysiology of, 1094–1105
    anatomic considerations, 1095–1099
    cerebral perfusion, 1099–1105
  staging prognosis in, 1108
  suspected child abuse in, 1065–1067
Health beliefs, cultural, and genetics, 58–59
Hearing loss, in Down syndrome, 35
Heart disease, congenital, in Down syndrome, 34
  in infant, emergency presentation of, 955–964
Heart failure, congestive, exacerbations of, 968–970
  in infant, lesions presenting with, 961–963
Hematocrit, in cyanotic cardiac patient, 971
Hematology, pediatric, future neuroimaging of, 794
Hemiparesis, in Sturge-Weber syndrome, 609
Hemoglobin, in cyanotic cardiac patient, 971
Hemoglobinopathies, and cyanosis, in infant, 1003
  molecular genetic analysis of, 100–101
Hemophilia, molecular genetic analysis of, 101
Hemorrhage, in central nervous system, imaging of, 753–759
Hemorrhagic shock, in trauma patient, 1087
Hepatic system, mitochondrial disease of, 324
Hermaphroditism, true, and ambiguous genitalia, 313–314
Herpes, genital, suspected sexual abuse in, 1077
Herpes simplex virus, congenital, nervous system infection by, 681–683
Heterozygote detection, with newborn screening, 208
Hip problems, in children's sports, 437–438
Histamine, as asthma mediator, 1210–1212
  challenge test with, in chronic asthma, 1297
  release of, in viral infection, 1265
Histochemical analysis, of muscle, in mitochondrial disorders, 331
History taking, in genetic counseling, 232
Hitting, as discipline technique, 408
HIV-1, and central nervous system, **691–714**
HIV infection, suspected sexual abuse in, 1077
HIV testing, in newborn, 208–209
Holoprosencephaly, and fetal death, 185
Homicide, prevention of, 480–481
Homocystinuria, neonatal screening tests for, 202
House dust mites, as allergens, in asthma, 1283–1284
Human immunodeficiency virus testing, in newborn, 208–209
Human parvovirus 19, and fetal death, 182
  as teratogen, 117–118
Human triploids, in genomic imprinting, 340
Hunger, factors affecting, 387, 389
Huntington's chorea, 737–738
Huntington's disease, genomic imprinting in, 344
Hybridization, definition of, 106
Hydantoin, as teratogen, 122–124
Hydration status, in cyanotic cardiac patient, 972
Hydrocephalus, magnetic resonance imaging of, 766
Hydrops fetalis, and fetal death, 182–183
Hydrosyringomyelia, magnetic resonance imaging of, 770
Hymen, appearance in child, 1075
Hyperactivity, diagnosis of, 905–908
  in attention deficits, 488
  temperament vs, 577–579
Hyperactivity disorder, diagnosis of, 577–578
Hyperammonemia, neurometabolic disorders with, laboratory studies of, 810, 812
Hypercyanotic spell, in cyanotic cardiac patient, 972
Hyperglycemia, nonketotic, laboratory studies of, 813
Hyperkalemia, with rhabdomyolysis, 832

Hypermetabolism, in burn injuries, 1155
Hyperphenylalaninemia, neonatal screening tests for, 202
Hyperphosphatemia, with rhabdomyolysis, 832
Hyperthermia, malignant, and rhabdomyolysis, 845–847
differential features of, 848–849
treatment of, 847
with Duchenne muscular dystrophy, 888
maternal, as teratogen, 119
Hyperventilation, confusion with asthma, 1333–1334
for intracranial hypertension, 1103
potential deleterious effects of, 1104
Hypnotherapy, for retentive encopresis, 424–425
Hypocalcemia, and cyanosis, in infant, 1002
Hypoglycemia, and cyanosis, in infant, 1002
Hypomelanotic macule, in tuberous sclerosis complex, 592
Hypoplastic left heart syndrome, in infant, and circulatory collapse, 964
Hypospadias, with ambiguous genitalia, 310
Hypothyroidism, central nervous system radiation and, 867
neonatal screening tests for, 202
Hypoventilation, central, and cyanosis, in infant, 999
Hypovigilance, clinical evaluation of, 908–909
treatment of, 919

IgM antibody, monoclonal, for bacterial meningitis, 653
Illness behavior, reactions to, behavioral assessment of, 375–376
Illness beliefs, cultural, and genetics, 58–59
Images, in mathematics learning, 527–528, 530
Imaging studies, in perinatal arterial distribution infarction, 633–634
of cerebral hypoperfusion, in preterm infant, 643–645
perinatal, 627–629
Imipramine, for affective illness, 914
Immersion burn, intentional, 1147
suspected child abuse in, 1058–1060
Immunizations, in Down syndrome, 39
Immunologic disorders, and fetal death, 178–181
Immunotherapy, for chronic asthma, 1306
Imprinting, genomic, 338–347. See also *Genomic imprinting*.
Impulsivity, as coping strategy, and low self-esteem, 543–544
in attention deficits, 488
Inattention, in attention deficits, 488
Independent play skills, teaching of, 402–403
Infant, benign myoclonus of, 739
cyanosis in, in emergency room, **987–1006**
full term, cerebral hypoperfusion in, 623–631
pulmonary function testing in, 1256–1257
wheezing in, risk factors for, 1186–1190
Infant mortality, in Down syndrome, 33–34
in trisomy 18, 40–41
Infantile myopathy, benign, phenotypes of, 321
Infantile spasms, functional brain imaging for, 785–789
Infection(s), and cyanosis, in infant, 996–997
central nervous system, congenital, **669–690**
serial evaluations for, 686
HIV-1–associated, 707–708
imaging of, 759–762
Infectious agents, and fetal death, 181–182
as teratogens, 115–118
cytomegalovirus, 116
human parvovirus 19, 117–118
rubella, 115
syphilis, 116
TORCH agents, 115
varicella, 116–117
Infective endocarditis, in cardiac patient, 967–969
Inferential reasoning, subtle weakness in, in adolescence, 519–520
Inflammatory cells, and asthma, 1209–1210
Influence, and social disabilities, 554–555
Inhalation anesthetics, for refractory status epilepticus, 1023
Inhalation injury, in burns, 1150
Inhaler, for asthma, correct technique for, 1356
Inheritance, cytoplasmic, 336–337
Mendel's laws of, 335–336
nontraditional, **335–348**
patterns of, in genomic imprinting, 345–346
Injuries, **471–485**
framework for considering, 471–472
prevention of, 475–478
intentional, 478–481

Injuries *(Continued)*
legislation and regulation, 477–478
persuasion and education in, 475–477
priorities in, 475
strategies for, 475
Insurance issues, in genetic couseling, 81
Intelligence, effect of central nervous system radiation on, 865–866
Intercellular adhesion molecule-1, in viral infection, 1264
Interleukin(s), mast cells as source of, in asthma, 1365–1366
role in bacterial meningitis, 652–653, 655
Intermittent explosive disorder, 723
Interpersonal disabilities, **551–567**
Intestinal perforation, suspected child abuse in, 1065
Intoeing, and clumsiness, 448
Intoxications, neurometabolic, 802
Intracranial compartment, pressure-volume relationship in, 1099–1100
Intracranial hypertension, and cerebrospinal fluid rhinorrhea, 660
compromised cerebral perfusion with, 1102
management steps in, 1111
pharmacologic management of, 1121–1122
prophylactic treatment of, 1112
with traumatic brain injury, 1095
Intracranial pressure, monitoring of, in head injury, 1094, 1111–1120
Intramedullary glioma, magnetic resonance imaging of, 770
Intrauterine growth retardation, uniparental disomy in, 342
Intraventricular hemorrhage, clinical signs and symptoms in, 637
electroencephalography in, 638–639
in preterm infant, 636–637
incidence of, 638
outcome in, 639
Ipecac, syrup of, use in poisoning, 1035, 1039–1040
Irritable bowel syndrome, treatment of, 423
Isoflurane, for refractory status epilepticus, 1023
Isolated children, peer acceptance/rejection of, 555–556
Isoniazid, for tuberculous meningitis, 664
Isotretinoin, and fetal death, 186
as teratogen, 128

Joint separation, with sports injury, 434
Jugular venous oxygen saturation, for cerebral oxygen delivery measurement, 1104–1105
Juvenile myoclonic epilepsy, 739

Karyotyping, in chromosome abnormalities, 237–238
Kawasaki disease, myocarditis in, 980–981
Kearns-Sayre syndrome, mitochondrial DNA deletions and, 326
with chronic progressive external ophthalmoplegia, 321–322
Ketoacidosis, neurometabolic disorders with, laboratory studies of, 808–809
Ketosis, neurometabolic disorders with, laboratory studies of, 808
Kidney, angiomyolipomas of, in tuberous sclerosis complex, 597
disease of, and fetal death, 183–184
trauma to, suspected child abuse in, 1065
Knee problems, in children's sports, 438–444
Kniest dysplasia, widened metaphyses in, 287
KSS/CPEO, mitochondrial disorders and, 321–322, 326

Laboraory services, in dysmorphology and clinical genetics, 358
Lactate, levels of, with forearm ischemic exercise, 836–837
skeletal muscle production of, 829
Lactate dehydrogenase, deficiency of, and rhabdomyolysis, 841
Lactic acidosis, congenital, phenotypes of, 321
in burn injuries, 1155
neurometabolic disorders with, laboratory studies of, 809–810
urine organic acid patterns in, 811
Language, test battery items for, 903
Language barriers, cultural factors in, and genetics, 61–62
Language disabilities, **513–524**
definition of, 514
developmental, perspective on, 513–518
specific, construct of, 514–515
Language processing, cognitive, weakness in, in adolescence, 518–523
Laryngomalacia, and cyanosis, in infant, 996
Laryngotracheobronchitis, and cyanosis, in infant, 995
Lead poisoning, 2,3–dimercaptosuccinic acid as antidote to, 1043–1044

Learning, 395–397
feedback in, 396–397
repetition in, 395–396
Learning disabilities, in neurofibromatosis type 1, 47–48
practical approach to, **895–928**. See also *School failure*.
recognition of, 901–905
treatment of, 911
Leber's hereditary optic neuropathy (LHON), mitochondrial DNA deletion in, 329
phenotypes of, 321
presentation of, 322
Leg problems, in children's sports, 444–445
Lennox-Gastaut syndrome, brain imaging in, 790–791
Leptomeningeal angiomatosis, in Sturge-Weber syndrome, 608, 612
Lessons, teaching of, role of discipline in, 398
Leukocyte inflammatory function, enhanced, in asthma, 1264–1266
Leukoencephalopathy, central nervous system radiation and, 867–868
Leukomalacia, periventricular, magnetic resonance imaging of, 756
Leukotrienes, as asthma mediators, 1211–1213
Levodopa, for torsion dystonia, 732
Lexical ambiguity, subtle weakness in, in adolescence, 520–521
Lidocaine, for status epilepticus, 1022
Ligament sprain, of ankle, in children's sports injury, 445
Limb-body wall complex, characteristics of, 268
definition of, 267
pathogenesis of, 269
Limb reduction defects, vascular disruption and, 270–272
Linkage analysis, definition of, 107–108
of genetic disorders, 95–97
Lip, lacerations of, treatment of, 1135
Lipid, membrane-derived, as asthma mediator, 1211–1212
Lipomyelomeningocele, cervico-occipital, magnetic resonance imaging of, 746
Lisch nodules, in neurofibromatosis, 601–602
Lithium, and fetal death, 186
as teratogen, 126
for manic illness, 916, 918
Liver rupture, suspected child abuse in, 1065
Logical processes, in mathematics learning, 528, 530
Loner children, peer acceptance/rejection of, 555–556
Long QT syndrome, syncope in, 717, 982
Loose joints, and clumsiness, 447
Lorazepam, for status epilepticus, 1017–1018
Lung function, initial, and wheezing in infancy, 1189–1190
Lyme disease, congenital, 684
Lysosomal storage diseases, in older child, detection of, 814–815

Mafenide acetate, for burn wound care, 1157
Magnesium compounds, catharsis with, for poisoning, 1038
Magnetic resonance imaging, for cerebral hypoperfusion, 627
of central nervous system, 743–744
of central nervous system hemorrhage, 754
Magnetic resonance spectroscopy, of muscle, in mitochondrial disorders, 331
Malformation, definition of, 141–142, 233
patterns of, teratogens and, 113–114
Malformation sequence, definition of, 147–148
Malignant hyperthermia, and rhabdomyolysis, 845–847
Mandibular angle, fracture of, 1139
Mania, criteria for, 907
treatment of, for school failure management, 912
Manipulations, in mathematics learning, 526–527, 530
Mannitol, for intracranial hypertension management, 1121
Maple syrup urine disease, neonatal screening tests for, 202
Maprotiline, for affective illness, 915
Mast cells, as source of interleukins, in asthma, 1365–1366
Maternal diseases, and AIDS risk factors, 692
and fetal death, 182
as teratogens, 118–119
Mathematics, child interview concerning, questions for, 531
fear of, control of, 533–534
mastery of, deficiencies in, **525–536**
performance in, parameters of, 531
subcomponents of, neurodevelopmental underpinnings of, 525–530
underachievement in, evaluation of, 530–531
potentiators of, 532
treatment of, 531–533
bypass techniques, 533

Mathematics *(Continued)*
management of neurodevelopmental dysfunctions, 533
underdeveloped subcomponents, 533
Maxillofacial trauma, **1127–1143**
antibiotics for, 1137–1138
examination of, 1128–1130
facial fractures in, 1138–1141
hemorrhage control in, 1130
soft-tissue injuries in, 1130–1138
avulsion, 1136
bites, 1136–1137
gunshot, 1136
surgical instruments for, 1131
treatment priorities in, 1129
McArdle's disease, and rhabdomyolysis, 834–839
Meckel-Gruber syndrome, and fetal death, 168–169
Medical illustrations and photography, in dysmorphology and clinical genetics, 357
Medical toxicology, update in, **1031–1051**
Medical treatment, for retentive encopresis, 424
Medication, as discipline technique, 408
Medicine, computer applications in, 1165–1166
computer-assisted diagnosis in, 1166–1169
algorithms for, 1168
bayesian logic in, 1166–1167
patient data bank in, 1167
referencing in, 1168–1169
MEDITEL-pediatric system, for computerized diagnostic referencing, 1168
Medulloblastoma(s), magnetic resonance imaging of, 766
staging of, 860
therapy of, 859–862
adjuvant chemotherapy, 860–861
radiation, 860
MELAS, mitochondrial DNA deletion in, 329
phenotypes of, 321
presentation of, 323
Memory, test battery items for, 903
Mendel, laws of inheritance of, 335–336
Mendelian syndromes, genetic counseling in, 246
Meningitis, and cyanosis, in infant, 999
bacterial, in children, **651–668**. See also *Bacterial meningitis*.
tuberculous, 663–665
Meningocele, and cerebrospinal fluid rhinorrhea, 660
cervico-occipital, magnetic resonance imaging of, 745–746
Menses, and worsening of asthma, 1332
Mental deterioration, in HIV-1–related progressive encephalopathy, 695
Mental retardation, **929–943**
autism and, 938–939
causes of, 930
cerebral palsy and, 939
chromosomal anomalies and, 931–934
definition of, 929
fragile-X, molecular genetic analysis of, 100
in HIV-1–related progressive encephalopathy, 695
in Sturge-Weber syndrome, 609
in tuberous sclerosis complex, 594
inborn errors of metabolism and, 938
teratogens and, 938
with multiple congenital anomalies, 936–937
MERRF, mitochondrial disorders and, 321–323, 329–330
Mesenteric vascular damage, suspected child abuse in, 1065
Mesomelia, definition of, 282–283
Metabolism, disorders of, and cyanosis, in infant, 1002
dystonia in, 735
inborn errors of, and mental retardation, 938
future neuroimaging of, 793
Metaphyses, dysplasia of, 291, 293
fractures of, suspected child abuse in, 1062–1063
Metatrophic dysplasia, 294
Methacholine challenge testing, of airway reactivity, in asthma, 1255, 1297
Methemoglobinemia, and cyanosis, in infant, 1002–1004
Methotrexate, as teratogen, 122
for central nervous system tumors, risks with, 870–871
low-dose, and chronic asthma, 1373
Methyl mercury, as teratogen, 126–127
Methylphenidate, for attention deficits, 503–505
for manic illness, 917–918
Methylprednisolone, for acute asthma, home therapy with, 1314
Microcephaly, with congenital cytomegalovirus, 680
with congenital toxoplasmosis, 675
Microvascular leakage, in airways, in asthma, 1214–1215
Microwave burns, suspected child abuse in, 1062
Midazolam, for status epilepticus, 1018
intramuscular administration of, 1021
Midbrain, cisterns of, obliteration of, 1099
perforating vessels of, herniation damage to, 1098

Middle ear, defect of, and cerebrospinal fluid fistula, 661
Migraine, complicated, and syncope, 718–719
Milk intake, during suckling, 381–382
Miller-Dieker syndrome, molecular genetic analysis of, 103
Mistakes, role in self-esteem, 547–548
Mitochondrial disorders, **319–334**
  biochemical genetic aspects of, 324–329
  clinical aspects of, 320–324
  definition of, 319
  laboratory diagnosis of, 329–332
  multisystem presentation of, 320–322
  phenotypes of, 321
  therapy of, 332
Mitochondrial DNA, alterations of, diseases with, 325–326
  mutation of, and mitochondrial disease, 326–329
    transmission of, 328
Mitochondrial metabolism, disorders of, and rhabdomyolysis, 841–845
    paracrystalline inclusions in, 844
Mitochondrial respiratory chain, defect of, and rhabdomyolysis, 843–845
    differential features of, 848–849
Molds, as allergens, in asthma, 1285–1286
Molecular analysis, genetic diagnosis based on, **91–109**
    basic concepts of, 93–97
    clinical applications of, 97–103
    techniques of, 92–93
Molecular biology, definitions in, 105–108
Molecular diagnosis, of muscle, in mitochondrial disorders, 331
Molecular genetics, in chromosome abnormality diagnosis, 238
Mondini defect, and cerebrospinal fluid fistula, 661–662
Morphine sulfate, for cyanotic cardiac patient, 973
Mosaicism, 337
Motor seizures, focal, brain imaging for, 788
Motor unit, of skeletal muscle, 824
Movement disorders, 721–722, **727–742**
  ballismus, 738
  chorea, 735–736
  classification of, 727–729
  dystonia, 721, 731–733
  Huntington's chorea, 737–738
  myoclonus, 738–740
  parkinsonism, 729–731
  paroxysmal choreoathetosis, 721
  shudder attacks, 722
  Syndenham's chorea, 736–737
  tic disorders, 721–722
  tremor, 740
Mucopolysaccharidoses, clinical features of, 815
Multifactorial inheritance, in birth defects, 247, 249
Multiple congenital anomaly syndromes, and ambiguous genitalia, 314–315
  with mental retardation, 303
  with skeletal dysplasia, 302–303
Multiple malformation syndromes, nonchromosomal, and fetal death, 167–174
Muscle, biopsy of, for Duchenne muscular dystrophy, 881, 883–886
  contractures of, with Duchenne muscular dystrophy, 887
  denervation of, and atrophy, 830
  disease of, rhabdomyolysis in, 821
  in mitochondrial disorders, 322, 331
  skeletal, normal, morphophysiology of, 823–830
    shortening and lengthening of, 828
Muscle fiber, damage to, responses of, 830–833
  energy metabolism defects in, and rhabdomyolysis, 833–834
  major components of, 825
  types of, characteristics of, 826
Muscular dystrophy, Duchenne, **879–894**. See also *Duchenne muscular dystrophy*.
  molecular genetic analysis of, 99–100
Mutation(s), detection of, effect of, 222
  genetic analysis of, direct, 94–95
    indirect, 95–97
Myelomeningocele, with secondary hydrocephalus, 148
Myoadenylate deaminase, deficiency of, and rhabdomyolysis, 845
    differential features of, 848–849
Myoblast transfer, for Duchenne muscular dystrophy, 890–891
Myocardial ischemia, chest pain in, 976
Myocarditis, chest pain in, 975–976
  in infant, congestive heart failure with, 963
  in Kawasaki disease, 980–981
Myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial DNA deletion in, 329
  pedigree and clinical characteristics of, 330
  phenotypes of, 321
  presentation of, 323
Myoclonus, 738–740
Myophosphorylase deficiency, and rhabdomyolysis, 834–839
  second-wind phenomenon in, 838
Myotonic dystrophy, genomic imprinting in, 344
Mysoline, as teratogen, 124

Nagging, as discipline technique, 407–408
Naloxone, administration of, in poisoning, 1032–1033, 1041
Narcolepsy, 720
clinical evaluation of, 909–910
treatment of, 919
Narcotics, and cyanosis, in infant, 1001
National Council on Self-Help and Public Health, 15
National Health and Nutrition Survey, asthma identification by, 1226–1227
Nedocromil sodium, for chronic asthma, 1298, 1303
Neglected children, peer acceptance/rejection of, 555–556
Neonate, death of, pediatrician's guide to, **157–192**
encephalopathies in, 625–626
perinatal cerebrovascular disease in, **621–650**
Neoplastic diseases, central nervous system, HIV-1–associated, 708
imaging of, 763–770
Nervous system, congenital infections of, **669–690**
cytomegalovirus, 678–681
herpes simplex virus, 681–683
microbiologic diagnosis of, 670
rubella, 676–678
syphilis, 669–674
toxoplasmosis, 674–676
in asthma, role of, 1215–1216
parasympathetic, 1216
sympathetic, 1216–1217
mitochondrial disease of, 322–323
Neu-Laxova syndrome, and fetal death, 171–172
Neurenteric fistula, and cerebrospinal fluid fistula, 662–663
Neuroblastoma, magnetic resonance imaging of, 769
Neurocutaneous syndromes, **591–620**
and mental retardation, 932
Neurodegenerative diseases, future neuroimaging of, 794–795
imaging of, 762–763
Neurodevelopmental dysfunctions, and mathematics underachievement, management of, 533
Neurofibromatosis, 600–607
brainstem glioma with, prognosis in, 863
cutaneous findings of, 600–601
diagnosis of, 607
neurologic complications of, 602–605
neuroradiology of, 605
of brain, magnetic resonance imaging of, 747
ophthalmologic findings in, 601–602
skeletal findings in, 606
type 1, 43–49, 101–102
anticipatory guidance and health supervision in, 49
clinics for, 48
diagnostic criteria for, 45–48
management of, guidelines for, 43–48
molecular genetic analysis of, 101–102
natural history of, 44
optic gliomas in, 46–47
vascular complications of, 605–606
Neuroimaging, functional, 777–778
future directions in, 793–795
in HIV-1–related progressive encephalopathy, 701–702
Neuroleptic drugs, and dystonia, 734
Neurologic function, in head injury, assessment of, 1106
Neurometabolic disorders, inherited, **801–820**
age at onset, 803
clinical approach to, 817
clinical classification of, 801–804
clinical features of, 804–807
distribution by category, 802
encephalopathies in, 803
frequency of, 803–806
gray and white matter, 802
in older child, detection of, 814–818
intoxications, 802
laboratory studies of, 807–814
small- and large-molecule, 802–803
types of, 809
urine screening tests for, 808
Neuromuscular disease, and cyanosis, in infant, 998–999
Neuronal ceroid lipofuscinoses, 816–818
Neuropathologic findings, in HIV-1–related progressive encephalopathy, 703
Neuropsychological profiles, in HIV-1–related progressive encephalopathy, 700–701
Neurotrauma, staging prognosis in, 1108
treatment algorithm for, 1110
Neurovascular disease, of central nervous system, imaging of, 753–759
Neutral endopeptidase deficiency, in viral respiratory infection, 1270
Neutrophil function, in viral infection, and airway hyperresponsiveness, 1266
Newborn screening, **199–211**
current issues in, 208–210
demographic data in, 205
diagnosis, management, treatment, and counseling in, 208
filter paper application in, 204–205
follow-up on, 207–208
in premature or sick infants, 206

practitioner's responsibilities in, 200–208
repeat of, 204
selection of tests for, 200
specimen collection and handling in, 201–206
sample transit to laboratory, 205–206
timing of test, 201, 204
type of blood sample for, 204–205
targeted, 206
with antibiotic therapy, 206
with hyperalimentation, 206
with infant transfer between hospitals, 206
with transfusions, 206
Nonbronchodilators, for asthma, clinical pharmacology of, 1219
Nonepileptic paroxysmal events, **715–725**
Nonsyndromic anomalies, genetic counseling for, 246–250
Nontraditional inheritance, **335–348**
Nonverbal communication, cultural factors in, and genetics, 60–61
Nortriptyline, for affective illness, 914
Nose, cartilage of, injury to, complications of, 1141
lacerations of, treatment of, 1135
obstruction of, and cyanosis, in infant, 995
Nuclear genomes, and mitochondrial disease, 325–326

Obesity, eating behavior and, 385–386
temperament and, 579
Oligodactyly, pathogenesis of, 271
Oncology, pediatric, future neuroimaging of, 794
Open Airways, for asthma self-management, 1345
Ophthalmologic abnormalities, in Down syndrome, 37–38
Opsoclonus, 739
Optic glioma(s), in neurofibromatosis, 602–603
type 1, 46–47
magnetic resonance imaging of, 748
Organization, problems with, stress-reduction for, 904
test battery items for, 903
Organophosphates, and cyanosis, in infant, 1001
Ornithine transcarbamylase deficiency, molecular genetic analysis of, 102
Osgood-Schlatter's disease, in children's sports injury, 440–441
Osseous lesions, in neurofibromatosis type 1, 45–46
Osteoblastoma, of cervical spine, computed tomography of, 768
Osteochondral fracture, of talus, in children's sports injury, 445
Osteochondritis, with congenital syphilis, 672
Osteochondritis dissecans, in children's sports injury, 442–443, 445
Osteogenesis imperfecta, in stillborn, 282, 298–299
rib fractures in, 295
Overactivity, and accident proneness, 473
Oxidative phosphorylation, in mitochondrial disorders, 324–329
respiratory chain-linked, 830
Oximetry, in acute asthma, with medically supervised therapy, 1316
in cyanotic cardiac patient, 971
Oxygen, supplemental, for acute asthma, with hospitalization, 1320
with medically supervised therapy, 1318–1319
Oxygen-hemoglobin dissociation curve, in cyanosis, 988
Oxygen tension, effect on cerebral blood flow, 1101
Oxygenation, in status epilepticus, 1011–1012

Pancreatic damage, suspected child abuse in, 1065
Panic attacks, 722–723
Panic disorder, confusion with asthma, 1333–1334
Paraldehyde, for status epilepticus, 1022
Paralytic ileus, in burn injuries, 1156
Parasagittal region, hypoperfusion of, imaging of, 625, 628–629
Parasympathetic nervous system, in asthma, role of, 1216
Parent(s), behavior of, and injury control, 473–474
manangement training in, for attention deficits, 506
coping skills of, 410
education/consent of, in newborn screening, 201
role in management of social skills problems, 560–561
Parkinsonism, 729–731
Paroxysmal events, nonepileptic, **715–725**
differential diagnosis of, 716
Parvovirus(es), congenital, 684
human, and fetal death, 182
as teratogen, 117–118
Passive-aggressive behavior, as coping strategy, and low self-esteem, 543

Patella, dislocation of, in children's sports injury, 444
Patello-femoral compression syndrome, in children's sports injury, 440–441
Patent ductus arteriosus, in infant, congestive heart failure with, 962
Patient education, in asthma, 1297, **1343–1361**. See also under *Asthma*.
Pattern injuries, suspected child abuse in, 1068
Patterns, in mathematics learning, 527, 530
Peak expiratory flow rate, home measurement of, technique of, 1355
in asthma, assessment of, 1297
meters for, 1246
monitoring of, 1312, 1322
testing of, 1251–1253
applications of, 1252
home use of, 1253
Pearson syndrome, mitochondrial DNA deletions and, 326
phenotypes of, 321
Pediatrician(s), collaborative planning with special educators, **451–469**
dysmorphologic diagnosis by, **135–156**
practical application of concept of temperament by, 580–582
role in management of social skills problems, 559–560
working with disabled children, suggestions for, 467
Pediatrics, central nervous system imaging in, **743–776**
functional brain imaging in, **777–799**
teratology in, **111–134**
Peer group, acceptance/rejection by, children categorized by, 555–556
and social disabilities, 554–555
Pelvis, skeletal dysplasia of, 299–300
PEM-DXP, for computerized diagnostic referencing, 1170–1173
advantages of, 1171–1173
diagnosis matchup screen for, 1171
diagnosis query screen for, 1170
diagnosis screen for, 1172–1173
Pemoline, for attention deficits, 504–505
for manic illness, 917–918
Pena-Shokeir syndrome, and fetal death, 171–173
Penetrating injury, in trauma patient, definitive care of, 1089–1090
Pentobarbital, for refractory status epilepticus, 1024
Perception, and social disabilities, 554–555
Performance inconsistency, in attention deficits, 488
Pericarditis, chest pain in, 974–975
Periorbital ecchymoses, suspected child abuse in, 1067
Periostitis, with congenital syphilis, 672
Periventricular cyst, folowing cerebral hypoperfusion in preterm infant, 642–643
Periventricular echodensities, with cerebral hypoperfusion in preterm infant, 640–641
Periventricular leukomalacia, cystic, with cerebral hypoperfusion in preterm infant, 645
electroencephalography in, 638–639
Peroxisomal disorders, laboratory studies of, 813–814
Pertussis syndrome, and cyanosis, in infant, 997
Phalanges, in skeletal dysplasia, 301–302
Phenobarbital, for status epilepticus, 1020
intramuscular administration of, 1021
intraosseous administration of, 1020
refractory, 1025
Phenotype, definition of, 106
Phenylketonuria, maternal, as teratogen, 118–119
molecular genetic analysis of, 102–103
neonatal screening tests for, 202
Phenytoin, for status epilepticus, 1018–1020
intraosseous administration of, 1020
Phenytoin prodrug, for status epilepticus, 1019–1020
intramuscular administration of, 1021
Phosphocreatine shuttle, of muscle fiber, 831
Phosphofructokinase, muscle deficiency of, and rhabdomyolysis, 839–840
Phosphoglycerate kinase, deficiency of, and rhabdomyolysis, 840–841
Phosphoglycerate mutase, muscle deficiency of, and rhabdomyolysis, 841
Phosphorylase *b* kinase, deficiency of, and rhabdomyolysis, 840
Photography, in dysmorphology and clinical genetics, 357
Physical examination, in genetic counseling, 232
Physical illness, temperament and, 579–580
Physical therapy, with full-thickness burns, 1160
Placenta, arterial to venous anastomoses in, twin studies of, 266–267
circulation of, disruption of, 258–260
examination of, in pregnancy loss, 163
Platelet-activating factor, as asthma mediator, 1211, 1214
Platyspondyly, 291, 294–295
Play skills, independent, teaching of, 402–403

Pleocytosis, lymphocytic, in tuberculous meningitis, 664
Plethysmography, for cerebral perfusion measurement, 1104
Pneumonia, and cyanosis, in infant, 993
Poison(ing), **1031–1051**
  and cyanosis, in infant, 1001–1002
  antidotes to, 1041–1046
  exposure to, toxic effects in, 1032
  gastric decontamination in, 1033–1041
  management of, initial, 1032–1033
  prevention of, 1046
  scope of problem in, 1031–1032
Pollen, as allergen, 1286–1287
Polydactyly, pathogenesis of, 271
Polymerase chain reaction, definition of, 107
  in molecular genetic diagnosis, 92–93
Poor children, injury risks in, 474–475
Popular children, peer acceptance of, 555
Popularity, social competencies associated with, 557
Positron emission tomography, of brain, 777–778
  of cerebral glucose metabolism, 780
  with epilepsy, 792–793
Posture, abnormal, in parkinsonism, 729
Potter phenotype, and fetal death, 183–184
Poverty, and asthma, 1197–1198
Practitioner's role, in newborn screening, **199–211**
Prader-Willi syndrome, chromosomal deletion syndrome in, 341
  molecular genetic analysis of, 103
  uniparental disomy in, 342
Prednisone, for acute asthma, home therapy with, 1314
  with medically supervised therapy, 1318
  for Duchenne muscular dystrophy, 890
Pregnancy, and worsening of asthma, 1331–1332
Pregnancy loss, diagnoses in, 160
  genetic counseling following, 186–187
  pediatrician's guide to, **157–192**
  study of, choice of studies for, 159–163
    chromosome studies in, 161–162
    fetal autopsy in, 162–163
    photographs in, 162
    placenta and cord, 162–163
    radiographic studies of, 162
    selection of babies for, 158–159
Prenatal diagnosis, ethical issues in, 85–86
  in mitochondrial disorders, 331
Primary care, behavioral assessment in, content of, 374–376
    functions of, 370–371
    inventories for, 374
    structure for, 372–374
    value of, 376
Primidone, as teratogen, 124
Problem-solving opportunities, in reinforcing self-esteem, 546
Procedures, in mathematics learning, 526, 530
Product modification, and injury prevention, 477–478
Pronuclear transplantation, in genomic imprinting, 339–340
Prostaglandin(s), as asthma mediators, 1211–1213
  for coarctation of aorta, in infant, 964
  for cyanotic infant, 958
Protein, depletion of, in burn injuries, 1156
Protriptyline, for affective illness, 915
Pseudoachondroplasia, 295
Pseudoseizures, 715–716
Pseudosyndactyly, amniotic bands and, 139
Psychological disorders, 722–723
  with Duchenne muscular dystrophy, 889
Psychotherapy, for attention deficits, 507
  for retentive encopresis, 424
Public health issues, in genetic couseling, 81
Pulmonary atresia with intact septum, cyanosis in, 960
Pulmonary blood flow, decreased, in cyanotic cardiac patient, 972
Pulmonary edema, and cyanosis, in infant, 993
Pulmonary function test(ing), in asthma, 1238, **1243–1258**
    clinical use of, 1247–1251
    equipment for, 1245–1246
    indications for, 1248–1249
    longitudinal testing in, 1250–1251
    reference populations for, 1249–1250
  in infant, 1256–1257
  normal values for, 1249
Pulmonary inflammation, chronic, airway hyperreactivity and, 1364
Pulmonary system, in cyanosis, 992–994
Pulmonic stenosis, cyanosis in, in infant, 990
Punishment, in encopresis treatment, 427–428
Purine nucleotide cycle, of muscle fiber, 831
Pyrazinamide, for tuberculous meningitis, 665

Quadriparesis, spastic, with perinatal cerebral hypoperfusion, 631

Quitting, as coping strategy, and low self-esteem, 542

Race, and asthma, 1197–1198
Radial aplasia, with vascular disruption, 262
Radiation, as teratogen, 127
Rape, examination for, 1074
Rationalizing, as coping strategy, and low self-esteem, 543
Reading, problems with, stress-reduction for, 904
  test battery items for, 903
Receptive language, subtle weakness in, in adolescence, 518–521
Record system, in dysmorphology and clinical genetics, 358–359
Rectal polyps, in tuberous sclerosis complex, 596–597
Reflectance oximetry, for cerebral perfusion measurement, 1104
Registries, of birth defects and genetic diseases, **65–77**
  applications of data from, 66–69
  ascertainment for, 71–72
  classification by clinical presentation, 75–76
  data collection methods for, 71–76
    birth defect data, 73–74
    coding of, 74
    demographic data, 73
    family history data, 74
    identifiers for, 72–73
    monitoring choices for, 75
    pregnancy data, 73
  diagnostic criteria for, 70
  disease definition for, 70
  eligibility for, 69–70
  hallmarks of, 69–70
  objectives of, 66–69
  study area/period of, 70
Regressing, as coping strategy, and low self-esteem, 543
Rejected children, peer acceptance/rejection of, 555
Relaxing factor, loss of, in viral respiratory infection, 1271
Renal agenesis, and fetal death, 183–184
  surveillance of, registries for, 68
Renal angiomyolipomas, in tuberous sclerosis complex, 597
Renal system, mitochondrial disease of, 323–324
Repetition, in learning, 396–397
Reproductive counseling, screening programs for, 83
Resource room, for disabled children, 460–461
Respiratory illness, congestive heart failure exacerbation vs, 969
Respiratory infections, and asthma, **1259–1276**
  microbiology of, 1259–1262
  in infancy, and development of asthma, 1190–1199
  viral, effect on airway responsiveness, 1267
Respiratory insufficiency, with Duchenne muscular dystrophy, 888
Respiratory rate, in acute asthma, 1312
Respiratory syncytial virus, and cyanosis, in infant, 996–997
  in cardiac patient, 970
Responsibility, development of, in reinforcing self-esteem, 545–546
Restriction enzymes, in molecular genetic diagnosis, 92
Restriction fragment length polymorphism, definition of, 106
Retina, astrocytoma of, in tuberous sclerosis complex, 594
  hemorrhages of, suspected child abuse in, 1066–1067
Retinoic acid, as teratogen, 128–129
Rewards, in encopresis treatment, 427–428
Rhabdomyolysis, **821–858**
  carbohydrate metabolism disorders and, 834–841
  causes of, 822
  differential features of, 848–849
  malignant hyperthermia and, 845–847
  mitochondrial metabolic disorders and, 841–845
  muscle fiber damage in, 832
  muscle fiber energy metabolism defects and, 833–834
  myoadenylate deaminase deficiency and, 845
  myophosphorylase deficiency and, 834–839
  supportive treatment for, 822
  toxin- or drug-related, differential features of, 848–849
Rhabdomyoma, cardiac, in tuberous sclerosis complex, 599
Rheumatic fever, and Syndenham's chorea, 736
  cardiac manifestations of, 981
Rhizomelia, definition of, 282
Rib fractures, in trauma patient, definitive care of, 1088
  suspected child abuse in, 1063
Ribavirin, for respiratory syncytial virus, 970
Rifampin, for tuberculous meningitis, 664–665
Rigidity, in parkinsonism, 729–730

Risk-taking behavior, and injury control, 474
Ritalin, for attention deficits, 503–505
Rodents, as allergens, in asthma, 1285
Rubella, as teratogen, 115
congenital, nervous system infection by, 676–678

Sacral agenesis, 147
Sagittal sinus thrombosis, computed tomography of, 757
Salary/benefits, in dysmorphology and clinical genetics, 358
Salter-Harris fracture(s), of growth plate, classification of, 437
type II, with sports injury, 434–435
Sandifer syndrome, 723, 733
Satiety, factors affecting, 387, 389
Scald burns, 1145–1146
suspected child abuse in, 1058–1060
time frame in, 1057
Scheuerrmen's disease, of spine, in children's sports injury, 446
School, as arena for social interaction, 554–555
School failure, **895–928**
clinical evaluation of, 898–910
determining diagnosis, 898–901
developmental history, 901
recognition of affective illness, 905–908
recognition of learning disabilities, 901–905
recognition of narcolepsy, 908–909
recognition of primary disorder of vigilance, 908–909
historical background on, 896–898
neurologic correlates of, 900
prognosis and management of, 910–919
constructive positive counseling, 910
curriculum adjustments, 911–912
treatment of affective illness, 912–919
School performance, role of temperament in, 575–576
School service programs, for disabled children, 459–462
Scoliosis, with Duchenne muscular dystrophy, 888
Screening, essential components of, 83
ethical issues in, 82–83
Sedatives, and cyanosis, in infant, 1001
for acute asthma, with intensive care, 1321
for intracranial hypertension management, 1121
Seizures, and cyanosis, in infant, 999
substances causing, 1009
treatment of, approach to, 1018
Self-discipline, establishment of, in reinforcing self-esteem, 547
Self-esteem, **537–550**
attribution theory in, 540–541
behavioral manifestations of, 541–544
biologic-temperamental influences in, 538–539
definition of, 537–538
environmental influences in, 539–540
reinforcement of, interventions for, 544–548
roots of, 538–540
Self-feeding, transition to, 385
Self-quieting skills, teaching of, 406
Sensitization, relevance to allergy, 1277–1279
Sentences, comprehension of, subtle weakness in, in adolescence, 519
in mathematics learning, 527, 530
Serotoninergic agents, for affective illness, 913
Sever disease, of ankle, in children's sports injury, 445
Sex chromosome abnormalities, diagnosis of, 237–238
Sexual abuse, recognition of, 1070–1075
behavioral symptoms, 1071
physical examination, 1072–1075
psychosocial assessment, 1071–1072
suspected, documentation of, 1078
Sexual differentiation, normal, genetic determinants of, 308
Sexually transmitted diseases, suspected sexual abuse in, 1076–1078
recommended laboratory procedures for, 1076
Shagreen patch, in tuberous sclerosis complex, 592–593
Shin splints, in children's sports injury, 444
Shock, and cyanosis, in infant, 997–998
cardiac disease and, 963–964
Shudder attacks, 722
Sickle cell disease(s), chest pain in, 976
molecular genetic analysis of, 100
neonatal screening tests for, 203
Silver nitrate, for burn wound care, 1157
Single gene abnormalities, and ambiguous genitalia, 311–314
syndromes caused by, 239–241
Single photon emission computed tomography, of brain, 778
Sinusitis, and asthma exacerbation, 1261, 1328–1329
Skeletal abnormalities, and fetal death, 174–175
in trisomy 18, 42
Skeletal dysplasia, approach to, **279–305**
categorization of, 302–303
definition of, 279

Skeletal dysplasia *(Continued)*
diagnosis of, 290
secure and specific establishment of, 304
sequential, 279–304
disproportion in, 281–282
identifying pattern of, 288, 291, 295, 299–302
laboratory studies in, 303
long bone shortening in, 282–285
of chest, 291, 295
of hands, 300–302
of head, 295, 299
of pelvis, 299–300
of spine, 291
recognition of, 281
secondary deformations in, documentation of, 286–288
identification of, 285–286
Skeletal injuries, suspected child abuse in, 1062–1064
Skeletal muscle. See *Muscle*.
Skillstreaming the Adolescent, for social skills training, 563
Skin grafting, in full-thickness burns, 1160
Skin pigmentation, and mental retardation, 932
Skull, fracture of, basilar, clinical signs of, 659
suspected child abuse in, 1067
sources of brain injury within, 1097
volume limitation of, effect in trauma, 1099
Slapping, as discipline technique, 408
Sleep apnea, and cyanosis, in infant, 999
Sleep apnea-hypersomnia syndrome, 720
Sleep disorders, 719–721
and asthma, 1332
narcolepsy, 720
night terrors, 719–720
nightmares, 719
somnambulism, 720–721
Sleep myoclonus, 738
Smoking, maternal, and wheezing in infancy, 1187
passive, and asthma, 1198–1199
Social disabilities, predisposing conditions for, 552–554
biologic factors, 552
cultural/ethnic factors, 554
developmental factors, 552–553
economic factors, 554
emotional factors, 553
familial factors, 553–554
Social interactions, types of, 557–558
Social memory/prediction, skills and competencies in, 556–557
Social relationships, behavioral assessment of, 374–375
Social skills, **551–567**
association with popularity, 557
problems in, assessment of, 558–559
management of, 559–564
role of parents in, 560–561
role of pediatricians in, 559–560
role of professionals in, 561
specific strategies in, 561–564
training programs for, 562–563
for attention deficits, 506
Social Skills in the Classroom, for social skills training, 563
Sodium bicarbonate, as poisoning antidote, 1042–1043
Soiling, manipulative, treatment of, 424
Solid food, eating of, transition to, 384–385
Somatic cell therapy, ethical issues in, 87
Somatic mosaicism, 337
Somnambulism, 720–721
Sorbitol catharsis, for poisoning, 1037–1038
Southern blot, definition of, 106–107
in molecular genetic diagnosis, 92–93
Spastic diplegia, neuroimaging of, 795
with cerebral hypoperfusion in preterm infant, 645
Special education, and supportive services, definition of, 458
historical background on, 452–454
programs for, children served by, 459
Special educators, collaborative planning with pediatricians, **451–469**
Spelling, problems with, stress-reduction for, 904
test battery items for, 903
Sphingolipidoses, clinical features of, 814
Spina bifida, surveillance of, registries for, 66–67
Spinal cord, abnormalities of, in HIV-1–related progressive encephalopathy, 703–704
tumors of, in neurofibromatosis, 602
Spinal muscular atrophy, molecular genetic analysis of, 103
Spine, defects of, and cerebrospinal fluid fistula, 662–663
infection of, imaging of, 761
malformations of, magnetic resonance imaging of, 745
neoplastic diseases of, imaging of, 767, 769
problems of, in children's sports, 446
skeletal dysplasia of, 291
Spiral fractures, suspected child abuse in, 1063
Spirogram, normal, 1244
Spirometry, performance of, in asthma, 1246–1247
Spleen rupture, suspected child abuse in, 1065

Split hand, pathogenesis of, 271
Spondyloepiphyseal dysplasia congenita, and dwarfism, 236
Sports injuries, in children, **433–449**
ankle, 445–446
growth plate, 433–437
hip, 437–438
knee, 438–444
leg, 444–445
spine, 446
Stab wounds, definitive care of, 1089–1090
Status epilepticus, **1007–1030**
etiology of, 1008–1009
management of, 1010–1015
approach to, 1025–1026
evaluation, 1013–1014
stabilization, 1011–1013
circulation and vascular access, 1012–1013
oxygenation and ventilation, 1011–1012
treatment overview, 1014–1015
pathophysiology of, 1007–1008
prognosis in, 1009–1010
refractory, control of, 1017
treatment of, 1022–1025
Steroids, for asthma, acute, home therapy with, 1314
poor use of, fatality risk in, 1233
for intracranial hypertension management, 1121–1122
Stillbirth, pediatrician's guide to, **157–192**
Stimulants, for attention deficits, 503–506
for learning disorders, 897
Streptomycin, for tuberculous meningitis, 664–665
Stress fracture, of leg, in children's sports injury, 444
Stroke, HIV-1–associated, 708
Structural anomalies, vascular disruption and, **255–277**
Sturge-Weber syndrome, 607–613
brain imaging in, 791–792
cutaneous features of, 607–609
diagnostic evaluation of, 610–611
management of, 612–613
neurologic manifestations of, 609–610
neuropathology of, 610
ophthalmologic complications of, 609
Subdural effusions, with meningitis, computed tomography of, 759
Subdural hematoma, suspected child abuse in, 1066
with head injury, treatment of, 1110
Subependymal nodules, in tuberous sclerosis complex, 596, 598
Subgaleal hematoma, suspected child abuse in, 1067
Subglottic stenosis, and cyanosis, in infant, 996
Suckling, development of, 381–383
regulation of, 386–389
Sudden infant death syndrome, and cyanosis, 999–1000
suspected child abuse in, 1069
Suffocation, and cyanosis, in infant, 1000–1001
Suicide, prevention of, 478–480
Sulfadiazine, for burn wound care, 1156
Sulfite oxidase deficiency, laboratory studies of, 813
Superstuff, for asthma self-management, 1345
Sweets, preference for, in heavy infants, 387
Symbol language, test battery items for, 903
Sympathetic nervous system, in asthma, role of, 1216–1217
Syncope, 717–719
cardiac causes of, 981–982
Syndactyly, pathogenesis of, 271
Syndenham's chorea, 736–737
Syndrome, definition of, 237
Syndromic anomalies, genetic counseling for, 244–246
Syphilis, as teratogen, 116
congenital, nervous system infection by, 669–674
suspected sexual abuse in, 1077
Syringomyelia, magnetic resonance imaging of, 753
Syrup of ipecac, for poisoning, 1035
advantages and disadvantages of, 1039–1040

Tachycardia, supraventricular, 977–980
congestive heart failure with, 963
Tarui's disease, and rhabdomyolysis, 839–840
Teaching My Parent/Myself About Asthma, for asthma self-management, 1345
Tectal tumor, magnetic resonance imaging of, 766
Tegison, as teratogen, 128
Tegmen tympani fracture, and cerebrospinal fluid fistula, 661
Tegretol, as teratogen, 123–124
Temperament, **569–584**
attention deficit/hyperactivity disorder vs, 577–579
changeability of, 572–573
concept of, limited acceptance of, 569–570

Temperament *(Continued)*
contribution to behavioral problems, 574–575
coping and, 580
effect on teachers' attitudes/evaluations, 576
in older child, congenital aspects of, 571–572
definition of, 570–571
importance of, 574, 579–580
measurement of, 573–574
obesity and, 579
physical illness and, 579–580
relationship of cognitive ability to, 576
role in school performance, 575–576
role of pediatrician in, education, 580
identification, 580–581
intervention, 581–582
practical application, 580–582
Temporal lobe astrocytoma, imaging of, 765
Temporal lobe epilepsy, cerebral glucose utilization in, 786–787
Temporal lobe hemorrhage, magnetic resonance imaging of, 752
Temporomandibular joint, fracture of, complications of, 1140–1141
Tension pneumothorax, in trauma patient, definitive care of, 1088
Teratogen(s), **111–134**
alcohol as, 119–122
aminopterin as, 122
and growth retardation, 113–114
and mental retardation, 937–938
carbamazepine as, 123–124
chemicals as, 119–129
cocaine as, 125–126
cytomegalovirus as, 116
diethylstilbestrol as, 126
drugs as, 119–129
effects of, 113–114
etretinate as, 128
human, 115–118
human parvovirus 19 as, 117–118
hydantoin as, 122–124
infection as, 115–118
isotretinoin as, 128
lithium as, 126
maternal disease as, 118–119
methotrexate as, 122
methyl mercury as, 126–127
primidone as, 124
radiation as, 127
retinoic acid as, 128–129
risks from, scientific studies of, 114
role of pediatrician in, 114–115
rubella as, 115
susceptibility to, genetic differences in, 113
syphilis as, 116
tetracycline as, 127
thalidomide as, 127
toluene as, 127–128
TORCH agents as, 115
trimethadione as, 124
valproic acid as, 124–125
varicella as, 116–117
vitamin A congeners as, 128
warfarin as, 129
Teratogenic syndromes, diagnosis of, 241
genetic counseling in, 246
Teratology, in pediatric practice, **111–134**
Testicular differentiation, genetic determinants of, 308
Tetracaine-adrenalin-cocaine, for topical anesthesia, in facial lacerations, 1133
Tetracycline, as teratogen, 127
Tetralogy of Fallot, cyanosis in, 959–960, 990
Thalassemias, molecular genetic analysis of, 100–101
Thalidomide, as teratogen, 127
Thanatophoric dysplasia, in newborn, 297
Theophylline, for asthma, acute, dosage guidelines for, 1315
home therapy with, 1314
chronic, 1298, 1301–1302
clinical pharmacology of, 1218
stage 2, 1295
Thiopental, for refractory status epilepticus, 1024
Thioridazine, for manic illness, 916
Threatening, as discipline technique, 407–408
Thrombocytopenia absent radius syndrome, radial aplasia with, 262
Thromboxanes, as asthma mediators, 1211–1213
Thyroid disorders, in Down syndrome, 35–36
Tibial bowing, 138
Tic disorders, 721–722
Time-in, as discipline technique, 400, 402
Time-out, as discipline technique, 400–407
conduct of, 407
ending of, 407
for behavior problems, 404–405
initiation of, 403
self-quieting skills, 406
warnings, 406–407
Toddlers, wheezing in, risk factors for, 1186–1190
Toilet training, behavioral management of, **413–432**
child-centered approach to, 415–416
how to train, 414–416
structured behavioral approach to, 416
when to train, 413–414
Toluene, as teratogen, 127–128
TORCH syndrome, imaging of, 760–761

teratogenic agents in, 115
Torsion dystonia, 731–733
Torticollis, 733
Total anomalous pulmonary venous return, cyanosis in, 960–961, 991–992
Toxicology, medical, update in, **1031–1051**
Toxoplasmosis, congenital, nervous system infection by, 674–676
Tracheomalacia, and cyanosis, in infant, 996
Traction alopecia, suspected child abuse in, 1067
Transgene expression, analysis of, in genomic imprinting, 344
Transposition of great arteries, cyanosis in, 958–959, 991
Transverse fractures, suspected child abuse in, 1063
Transverse limb defect, pathogenesis of, 271
Trauma, central nervous system, computed tomographic imaging of, 750–753
  patient with, assessment and treatment of, **1083–1091**
    definitive care of, 1088–1090
    infant, cyanosis in, 1000–1001
    initial assessment of, 1083–1086
    resuscitation of, 1086–1087
    secondary survey of, 1088
    trauma scores in, 1085
    triage of, 1083–1086
Trazodone, for affective illness, 915
Tremor, 740
  in parkinsonism, 729
Triamcinolone acetonide, for asthma, maximum recommended doses for, 1304
Trichomonas infection, suspected sexual abuse in, 1077
Tricuspid atresia, cyanosis in, 960, 990–991
Tricyclic antidepressants, for affective illness, 913, 918
  for attention deficits, 504–506
  sodium bicarbonate as antidote to, 1042–1043
Tridione, as teratogen, 124
Trimethadione, and fetal death, 186
  as teratogen, 124
Triploids, human, in genomic imprinting, 340
Trisomy 18, infant mortality in, 40–41
  management of, guidelines for, 40–43
  medical complications in, 41–43
  psychosocial family support in, 43
Trisomy 12 mosaicism, 167
Truncus arteriosus, cyanosis in, in infant, 991
Trunk, short, causes of, 284–285
Trypanosomiasis, congenital, 684
Tuberculosis, and cyanosis, in infant, 993
Tuberculous meningitis, 663–665
Tuberous sclerosis complex, 591–600
  cutaneous features of, 592–593
  diagnostic criteria for, 597, 600
  genetics of, 599–600
  neurologic manifestations of, 594–595
  neuropathology of, 595–596
  neuroradiology of, 596
  ophthalmologic features of, 594
  organ involvement in, 596–599
Tumor(s), central nervous system, **859–877**. See also *Central nervous system, tumors of.*
Tumor necrosis factor, cerebrospinal fluid, role in bacterial meningitis, 652
Turner syndrome, chromosome analysis of, 240
  phenotypic range of, 166
Twin(s), malformations in, and fetal death, 175–178
Twin reversed arterial perfusion sequence, 178
  development of, 260
  patterns of, 261
  radial aplasia with, 262
Twin studies, of vascular disruption, 266–267
Twin-to-twin transfusion syndrome, 179
Tyrosinemia, neonatal screening tests for, 202

Ultrasonography, for cerebral hypoperfusion, 627–629
  of central nervous system, primary uses of, 744
Umbilical cord, examination of, in pregnancy loss, 163
Ungual fibromas, in tuberous sclerosis complex, 592–593
Uniparental disomy, 338
  in genomic imprinting, 342–343
Upper airway obstruction, and cyanosis, in infant, 994–996
Urine organic acid, patterns of, in congenital lactic acidosis, 811
Urine screening, routine, in newborn, 209

Valproic acid, and fetal death, 186
  as teratogen, 124–125
  for status epilepticus, rectal administration of, 1021–1022
Values, in genetic counseling, 79–81
  teaching of, role of discipline in, 398–399

Varicella, as teratogen, 116–117
Varicella-zoster virus, congenital, 684
Vascular access, in status epilepticus, 1012–1013
Vascular disease, of central nervous system, imaging of, 753–759
Vascular disruption, **255–277**
  and limb body wall complex, 267–269
  and limb reduction defects, 270–272
  in embryo and fetus, 257–258
  in twins, events leading to, 266
  mechanisms of, blood vessel embryology and, 256–265
  role of cocaine in, 272–273
  structural anomalies from, diagnostic investigations of, 273
    evidence for, 265–273
    prenatal diagnosis of, 274
    recurrence risk of, 274
Ventilation, assisted, for acute asthma, with intensive care, 1321
  in status epilepticus, 1011–1012
Ventilation/perfusion mismatch, and cyanosis, in infant, 992
Ventricular effacement, with diffuse brain edema, 1113
Ventricular enlargement, in HIV-1–related progressive encephalopathy, 704–705
Ventricular septal defect, in infant, congestive heart failure with, 962
Ventricular tacycardia, 980
Ventriculostomy, for intracranial pressure monitoring, in head injury, 1109, 1112
    bedside, 1113, 1114–1120
    catheter insertion in, 1118
    landmark for, 1116
    protocol for, 1110
    scalp preparation for, 1116
    subcutaneous seating in, 1119
    twist drill for, 1114, 1117
Verapamil, for supraventricular tachycardia, 979
Verbal pragmatics, skills and competencies in, 556
Verbal reasoning, subtle weakness in, in adolescence, 519
Vertebrae, deformities of, magnetic resonance imaging of, 753
  fracture of, computed tomography of, 752
Vigilance, primary disorder of, clinical evaluation of, 908–909
    treatment of, 919
Viral infections, pulmonary, and asthma, **1259–1276**
    and cyanosis, in infant, 993
Vitamin A congeners, as teratogens, 128
Vitelline circulation, disruption of, 258–260
Vocabulary, problems with, stress-reduction for, 904
Vocal cord dysfunction, confusion with asthma, 1333
Vomiting, induced, in poisoning, 1035
von Recklinghausen's disease, 600–607

Waksman Social Skills Curriculum, for social skills training, 563
Walker-Warburg syndrome, and fetal death, 169–171
Warfarin, and fetal death, 186
  as teratogen, 129
Warning, as discipline technique, 407–408
Weakness, with myophosphorylase deficiency, 835
Welts, suspected child abuse in, 1068
Wheezing, risk factors for, **1185–1203**
    in infancy, 1186–1190
      endogenous, 1188
      exogenous, 1186–1188
      immunologic, 1188–1190
Whiplash shaken infant syndrome, child abuse in, 1066
White matter, abnormalities of, in HIV-1–related progressive encephalopathy, 701, 703
  lesions of, in tuberous sclerosis complex, 598
  neurometabolic disorders of, 802
Whole bowel irrigation, for poisoning, 1038–1039
    advantages and disadvantages of, 1040
Wilms tumor-aniridia syndrome, and ambiguous genitalia, 311
Wilson's disease, dystonia in, 734
Word comprehension, in mathematics learning, 527, 530
  subtle weakness in, in adolescence, 518
Wrath of math, **525–536**
Writing, problems with, stress-reduction for, 904

X-linked inheritance, in birth defects, 241
XX males, and ambiguous genitalia, 311

Zygomatico-maxillary complex, fracture of, 1140–1141